The surgical treatment of a patient with localized renal cancer and chronic renal failure following a course of stereotactic radiotherapy ; Хирургическое лечение пациентки с локализованным раком почки и хронической почечной недостаточностью после курса стереотаксической лучевой терапии

Συγγραφείς: G. V. Gilivanova, E. A. Kipriyanov, P. A. Karnaukh, K. Y. Ivakhno, A. A. Peretrukhin, M. A. Zolotykh, M. T. Beydzhanov, D. M. Rostovtsev, Г. В. Гиливанова, Е. А. Киприянов, П. А. Карнаух, К. Ю. Ивахно, А. А. Перетрухин, М. А. Золотых, М. Т. Бейджанов, Д. М. Ростовцев

Πηγή: Urology Herald; Том 13, № 1 (2025); 82-87 ; Вестник урологии; Том 13, № 1 (2025); 82-87 ; 2308-6424 ; 10.21886/2308-6424-2025-13-1

Θεματικοί όροι: скорость клубочковой фильтрации, kidney resection, stereotactic radiation therapy, glomerular filtration rate, резекция почки, стереотаксическая лучевая терапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.urovest.ru/jour/article/view/1016/626; Аксель Е.М., Матвеев В.Б. Статистика злокачественных новообразований мочевых и мужских половых органов в России и странах бывшего СССР. Онкоурология. 2019;15(2):15-24. DOI:10.17650/1726-9776-2019-15-2-15-24; Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913-924. DOI:10.1016/j.eururo.2015.01.005; Рак паренхимы почек. Рубрикатор клинических рекомендаций Министерства здравоохранения Российской Федерации. Ссылка активна на 03.03.2024. URL: https://cr.minzdrav.gov.ru/schema/10_4; Оганян В.А., Карельская Н.А., Монаков Д.М., Демидова В.С., Лебедева А.Н., Грицкевич А.А. Робот-ассистированная резекция почки при сложных новообразованиях с применением интракорпоральной изолированной фармакохолодовой ишемии in situ. Вестник урологии. 2024;12(5):96-104. DOI:10.21886/2308-6424-2024-12-5-96-104; Котов С.В., Гуспанов Р.И., Юсуфов А.Г., Неменов А.А., Манцов А.А. Влияние adherent perinephric fat на результаты органосохраняющего лечения почечно-клеточного рака. Вестник урологии. 2023;11(2):47-55. DOI:10.21886/2308-6424-2023-11-2-47-55; Ивахно К.Ю., Важенин А.В., Карнаух П.А., Галлямова Ю.В., Важенин И.А. Первый опыт применения роботизированной системы для стереотаксической гипрофракционной радиотерапии «Кибернож» в лечении пациентов с почечно-клеточным раком. Тюменский медицинский журнал. 2015;17(1):28-31. eLIBRARY ID: 23867907; EDN: UCHVOF; Серегин А.А., Серегин А.В., Колонтарев К.Б., Пушкарь Д.Ю., Лоран О.Б. Сравнение открытой, лапароскопической и роботической техник резекции почки по критериям «трифекта» и «пентафекта» при почечно-клеточном раке. Вестник урологии. 2024;12(2):66-75. DOI:10.21886/2308-6424-2024-12-2-66-75; Ракул С.А., Поздняков К.В., Елоев Р.А. Отдаленные онкологические результаты хирургического лечения локализованных опухолей почек. Онкоурология. 2021;17(4):27-37. DOI:10.17650/1726-9776-2021-17-4-27-37; Senger C, Conti A, Kluge A, Pasemann D, Kufeld M, Acker G, Lukas M, Grün A, Kalinauskaite G, Budach V, Waiser J, Stromberger C. Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function. BMC Urol. 2019;19(1):96. DOI:10.1186/s12894-019-0531-z; Correa RJM, Louie AV, Staehler M, Warner A, Gandhidasan S, Ponsky L, Ellis R, Kaplan I, Mahadevan A, Chu W, Swaminath A, Onishi H, Teh BS, Lo SS, Muacevic A, Siva S. Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK. J Urol. 2019;201(6):1097-1104. DOI:10.1097/JU.0000000000000111; Siva S, Pham D, Kron T, Bressel M, Lam J, Tan TH, Chesson B, Shaw M, Chander S, Gill S, Brook NR, Lawrentschuk N, Murphy DG, Foroudi F. Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial. BJU Int. 2017;120(5):623-630. DOI:10.1111/bju.13811; Черниченко А.В., Корнилов И.В., Воробьёв Н.В., Плавник Р.Н., Гольбиц А.Б., Леонтьев А.В., Герасимов В.А. Стереотаксическая лучевая терапия ранних форм рака почки. Онкология. Журнал им. П.А. Герцена. 2024;13(5):5 11. DOI:10.17116/onkolog2024130515; Степанович Е.А., Демешко П.Д., Поляков С.Л., Минайло И.И. Стереотаксическая лучевая терапия при почечно-клеточном раке. Опыт и непосредственные результаты. Злокачественные опухоли. 2022;12(3s1):57-61. DOI:10.18027/2224-5057-2022-12-3s1-57-61; https://www.urovest.ru/jour/article/view/1016

Διαθεσιμότητα: https://www.urovest.ru/jour/article/view/1016
https://doi.org/10.21886/2308-6424-2024-12-5-82-87

Metastasis-directed therapy for metachronous metastases of prostate cancer ; Метастазнаправленная терапия метахронных олигометастазов рака предстательной железы

Συγγραφείς: A. V. Sarkisyan, P. V. Bulychkin, A. V. Khachaturyan, A. A. Kufelkina, D. D. Ladyko, А. В. Саркисян, П. В. Булычкин, А. В. Хачатурян, А. А. Куфелкина, Д. Д. Ладыко

Πηγή: Cancer Urology; Том 20, № 4 (2024); 55-59 ; Онкоурология; Том 20, № 4 (2024); 55-59 ; 1996-1812 ; 1726-9776

Θεματικοί όροι: стереотаксическая лучевая терапия, metachronous oligometastases, hormone-sensitive prostate cancer, stereotactic radiation therapy, метахронные олигометастазы, гормоночувствительный рак предстательной железы

Περιγραφή αρχείου: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1833/1582; Состояние онкологической помощи населению России в 2021 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 239 с.; Cornford P., Bellmunt J., Bolla M. et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 2017;71(4):630–42. DOI:10.1016/j.eururo.2016.08.002; Hellman S., Weichselbaum R.R. Oligometastases. J Clin Oncol 1995;13(1):8–10. DOI:10.1200/JCO.1995.13.1.8; Phillips R., Yue Shi W., Deek M. et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 2020;6(5):650–9. DOI:10.1001/jamaoncol.2020.0147; Palma D.A., Olson R., Harrow S. et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 2020;38:2830–8. DOI:10.1200/JCO.20.00818; Tang C., Sherry A.D., Haymaker C. et al. Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial. JAMA Oncol 2023;9(6):825–34. DOI:10.1001/jamaoncol.2023.0161; https://oncourology.abvpress.ru/oncur/article/view/1833

Διαθεσιμότητα: https://oncourology.abvpress.ru/oncur/article/view/1833
https://doi.org/10.17650/1726-9776-2024-20-4-55-59

Modern approaches to treatment of tumors of the solitary kidney ; Современные подходы в лечении опухолей единственной почки

Συγγραφείς: S. B. Petrov, I. V. Zyatchin, S. A. Reva, С. Б. Петров, И. В. Зятчин, С. А. Рева

Πηγή: Cancer Urology; Том 20, № 3 (2024); 142-151 ; Онкоурология; Том 20, № 3 (2024); 142-151 ; 1996-1812 ; 1726-9776

Θεματικοί όροι: стереотаксическая лучевая терапия, partial nephrectomy, tyrosine kinase inhibitor, thermal ablation, stereotactic radiotherapy, резекция почки, ингибитор тирозинкиназы, термальная аблация

Περιγραφή αρχείου: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1804/1564; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1804/1504; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1804/1505; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1804/1506; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1804/1507; EAU Guidelines. Edn. presented at the EAU Annual Congress Milan March 2023.; Campbell S.C., Clark P.E., Chang S.S. et al. Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA Guideline: Part I. J Urol 2021;206(2):199–208. DOI:10.1097/JU.0000000000001911; Saranchuk J.W., Touijer A.K., Hakimian P. et al. Partial nephrectomy for patients with a solitary kidney: the Memorial Sloan-Kettering experience. BJU Int 2004;94(9):1323–8. DOI:10.1111/j.1464-410X.2004.05165.x; Ghavamian R., Cheville J.C., Lohse C.M. et al. Renal cell carcinoma in the solitary kidney: an analysis of complications and outcome after nephron sparing surgery. J Urol 2002;168(2):454–9. DOI:10.1016/s0022-5347(05)64657-5; Fergany A.F., Saad I.R., Woo L., Novick A.C. Open partial nephrectomy for tumor in a solitary kidney: experience with 400 cases. J Urol 2006;175(5):1630–3; discussion 1633. DOI:10.1016/S0022-5347(05)00991-2; La Rochelle J., Shuch B., Riggs S. et al. Functional and oncological outcomes of partial nephrectomy of solitary kidneys. J Urol 2009;181(5):2037–42; discussion 2043. DOI:10.1016/j.juro.2009.01.024; Mues A.C., Korets R., Graversen J.A. et al. Clinical, pathologic, and functional outcomes after nephron-sparing surgery in patients with a solitary kidney: a multicenter experience. J Endourol 2012;26(10):1361–6. DOI:10.1089/end.2012.0114; Ching C.B., Lane B.R., Campbell S.C. et al. Five to 10-year followup of open partial nephrectomy in a solitary kidney. J Urol 2013;190(2):470–4. DOI:10.1016/j.juro.2013.03.028; Матвеев В.Б., Волкова М.И., Алборов С.В. и др. Резекция единственной функционирующей почки при опухолях почечной паренхимы. Онкоурология 2017;13(2):27–35. DOI:10.17650/1726-9776-2017-13-2-27-35; Hillyer S.P., Bhayani S.B., Allaf M.E. et al. Robotic partial nephrectomy for solitary kidney: a multi-institutional analysis. Urology 2013;81(1):93–7. DOI:10.1016/j.urology.2012.08.055; Panumatrassamee K., Autorino R., Laydner H. et al. Robotic versus laparoscopic partial nephrectomy for tumor in a solitary kidney: a single institution comparative analysis. Int J Urol 2013;20(5):484–91. DOI:10.1111/j.1442-2042.2012.03205.x; Zargar H., Bhayani S., Allaf M.E. et al. Comparison of perioperative outcomes of robot-assisted partial nephrectomy and open partial nephrectomy in patients with a solitary kidney. J Endourol 2014;28(10):1224–30. DOI:10.1089/end.2014.0297; Benichou Y., Audenet F., Bensalah K. et al. Partial nephrectomy in solitary kidneys: comparison between open surgery and roboticassisted laparoscopy on perioperative and functional outcomes (UroCCR-54 study). World J Urol 2023;41(2):315–24. DOI:10.1007/s00345-022-04026-y; Beksac A.T., Okhawere K.E., Abou Zeinab M. et al. Robotic partial nephrectomy for management of renal mass in patients with a solitary kidney: can we expand the indication to T2 and T3 disease? Minerva Urol Nephrol 2022;74(2):203–8. DOI:10.23736/S2724-6051.22.04671-7; Lane B.R., Novick A.C., Babineau D. et al. Comparison of laparoscopic and open partial nephrectomy for tumor in a solitary kidney. J Urol 2008;179(3):847–51; discussion 852. DOI:10.1016/j.juro.2007.10.050; Lane B.R., Derweesh I.H., Kim H.L. et al. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. Urol Oncol 2015;33(3):112.e15–21. DOI:10.1016/j.urolonc.2014.11.009; Hellenthal N.J., Underwood W., Penetrante R. et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol 2010;184(3):859–64. DOI:10.1016/j.juro.2010.05.041; Silberstein J.L., Millard F., Mehrazin R. et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int 2010;106(9):1270–6. DOI:10.1111/j.1464-410X.2010.09357.x; Gorin M.A., Ekwenna O., Soloway M.S., Ciancio G. Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery. Urology 2012;79(2):e11. DOI:10.1016/j.urology.2011.04.018; Tochigi K., Funahashi Y., Mori A. et al. Pre-surgical sunitinib treatment enabling nephron-sparing surgery in a patient with renal cell carcinoma in a solitary kidney. Nagoya J Med Sci 2019;81(2):337–40. DOI:10.18999/nagjms.81.2.337; Powers M.K., Sartor O., Lee B.R. Neoadjuvant tyrosine kinase downstaging of T2 renal cell carcinoma in solitary kidney before robotic partial nephrectomy. J Endourol Case Rep 2015;1(1):47–9. DOI:10.1089/cren.2015.0005; Rini B.I., Plimack E.R., Takagi T. et al. A phase II study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma. J Urol 2015;194(2):297–303. DOI:10.1016/j.juro.2015.03.096; Hakimi K., Campbell S.C., Nguyen M.V. et al. PADRES: a phase 2 clinical trial of neoadjuvant axitinib for complex partial nephrectomy. BJU Int 2024;133(4):425–31. DOI:10.1111/bju.16217; Weisbrod A.J., Atwell T.D., Frank I. et al. Percutaneous cryoablation of masses in a solitary kidney. AJR Am J Roentgenol 2010;194(6):1620–5. DOI:10.2214/AJR.09.2978; Bhindi B., Mason R.J., Haddad M.M. et al. Outcomes after cryoablation versus partial nephrectomy for sporadic renal tumors in a solitary kidney: a propensity score analysis. Eur Urol 2018;73(2):254–9. DOI:10.1016/j.eururo.2017.09.009; Haber G.P., Lee M.C., Crouzet S. et al. Tumour in solitary kidney: laparoscopic partial nephrectomy vs laparoscopic cryoablation. BJU Int 2012;109(1):118–24. DOI:10.1111/j.1464-410X.2011.10287.x; Yasuda Y., Zhang J.H., Attawettayanon W. et al. Comprehensive management of renal masses in solitary kidneys. Eur Urol Oncol 2023;6(1):84–94. DOI:10.1016/j.euo.2022.11.004; Siva S., Ali M., Correa R.J.M. et al. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Lancet Oncol 2022;23(12):1508–16. DOI:10.1016/S14702045(22)00656-8; Correa R.J.M., Louie A.V., Staehler M. et al. Stereotactic radiotherapy as a treatment option for renal tumors in the solitary kidney: a multicenter analysis from the IROCK. J Urol 2019;201(6):1097–104. DOI:10.1097/JU.0000000000000111; Pierorazio P.M., Johnson M.H., Ball M.W. et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur Urol 2015;68(3):408–15. DOI:10.1016/j.eururo.2015.02.001; Roussel E., Laenen A., Bhindi B. et al. Predicting short- and longterm renal function following partial and radical nephrectomy. Urol Oncol 2023;41(2):110.e1–6. DOI:10.1016/j.urolonc.2022.10.006; https://oncourology.abvpress.ru/oncur/article/view/1804

Διαθεσιμότητα: https://oncourology.abvpress.ru/oncur/article/view/1804
https://doi.org/10.17650/1726-9776-2024-20-3-142-151

Метастатическое поражение центральной нервной системы

Συγγραφείς: Д. Р. Насхлеташвили, С. М. Банов, А. Х. Бекяшев, А. В. Голанов, А. М. Зайцев, Г. Л. Кобяков, А. И. Пронин, А. В. Смолин

Πηγή: Malignant tumours; Том 14, № 3s2-1 (2024); 212-220 ; Злокачественные опухоли; Том 14, № 3s2-1 (2024); 212-220 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: нейрохирургическое лечение, таргетная терапия, химиотерапия, иммунотерапия, лучевая терапия, стереотаксическая лучевая терапия, радиохирургия

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1367/972; https://www.malignanttumors.org/jour/article/view/1367

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/1367
https://doi.org/10.18027/2224-5057-2024-14-3s2-1.1-11

Comparative analysis of the results of surgical and radiation treatment of stage I kidney cancer ; Сравнительный анализ результатов хирургического и лучевого лечения I стадии рака почки

Συγγραφείς: Zh. Е. Sabelnikova, М. М. Sarycheva, Е. Ya. Mozerova, А. V. Vazhenin, А. А. Lozhkov, Ж. Е. Сабельникова, М. М. Сарычева, Е. Я. Мозерова, А. В. Важенин, А. А. Ложков

Συνεισφορές: The article was prepared without sponsorship, Статья подготовлена без спонсорской поддержки

Πηγή: Malignant tumours; Том 14, № 2 (2024); 44-50 ; Злокачественные опухоли; Том 14, № 2 (2024); 44-50 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: почечная токсичность, kidney resection, nephrectomy, stereotactic radiation therapy, renal toxicity, резекция почки, нефрэктомия, стереотаксическая лучевая терапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1312/943; Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 252 с.; Клинические рекомендации. Злокачественные новообразования паренхимы почки, 2021. Доступно по: https://cr.minzdrav.gov.ru/recomend/10_2; Gill I.S., Kavoussi L.R., Lane B.R., et al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol 2007;178(1):41–6. doi:10.1016/j.juro.2007.03.038; Magee D.E., Wong J.K., Correa A.F. Stereotactic ablative body radiotherapy: an emerging weapon in the treatment armamentarium for renal cell carcinoma or a potential avenue for overtreatment? Eur Urol 2022;82(6):623–624. doi:10.1016/j.eururo.2022.07.020; Mir M.C., Derweesh I., Porpiglia F., et al. Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors : a systematic review and meta‑analysis of comparative studies. Eur Urol 2017;71(4):606−17. doi:10.1016/j.eururo.2016.08.060; Forbes C.M., Rendon R.A., Finelli A., et al. Disease progression and kidney function after partial vs. radical nephrectomy for T1 renal cancer. Urol Oncol 2016;34(11):486.e17−23. doi:10.1016/j.urolonc.2016.05.034.; Jiang Y.L., Peng C.X., Wang H.Z., Qian L.J. Comparison of the long‑term follow‑up and perioperative outcomes of partial nephrectomy and radical nephrectomy for 4 cm to 7 cm renal cell carcinoma : a systematic review and meta‑analysis. BMC Urol 2019;19(1):48. doi:10.1186/s12894-019-0480-6; Rühle A., Andratschke N., Siva S., Guckenberger M. Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma? Clin Transl Radiat Oncol 2019;18:104–112. doi:10.1016/j.ctro.2019.04.012; Haque W., Verma V., Lewis G.D., et al. Utilization of radiotherapy and stereotactic body radiation therapy for renal cell cancer in the USA. Future Oncol 2018;14(9):819–827. doi:10.2217/fon-2017-0536.; Ali M., Mooi J., Lawrentschuk N., et al. The role of stereotactic ablative body radiotherapy in renal cell carcinoma. Eur Urol 2022;82(6):613–622. doi:10.1016/j.eururo.2022.06.017; Siva S., Ali M., Correa R.J.M., et al. 5‑year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta‑analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Lancet Oncol 2022;23(12):1508–1516. doi:10.1016/S1470-2045(22)00656-8; Siva S., Pham D., Kron T., et al. Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial. BJU Int 2017;120(5):623–630. doi:10.1111/bju.13811; Siva S., Ellis R.J., Ponsky L., et al. Consensus statement from the International radiosurgery oncology consortium for kidney for primary renal cell carcinoma. Future Oncol 2016;12(5):637–45. doi:10.2217/fon.16.2; Grant S.R., Lei X., Hess K.R., et al. Stereotactic body radiation terapy for the definitive treatment of early stage kidney cancer: a survival comparison with surgery, tumor ablation, and observation. Adv Radiat Oncol 2020;5(3):495–502. doi:10.1016/j.adro.2020.01.002.; https://www.malignanttumors.org/jour/article/view/1312

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/1312
https://doi.org/10.18027/2224-5057-2024-009

Metastatic Spinal Lesion with Minimal Epidural Compression: Surgical Treatment or Stereotactic Radiotherapy? ; Метастатическое поражение позвоночника с минимальной эпидуральной компрессией: хирургическое лечение или стереотаксическая лучевая терапия?

Συγγραφείς: O. I. Kit, D. E. Zakondyrin, A. A. Grin, E. E. Rostorguev, Y. V. Przhedetskiy, P. G. Sakun, V. I. Voshedskii, B. V. Matevosian, T. S. Shepelya, О. И. Кит, Д. Е. Закондырин, А. А. Гринь, Э. Е. Росторгуев, Ю. В. Пржедецкий, П. Г. Сакун, В. И. Вошедский, Б. В. Матевосян, Т. С. Шепеля

Πηγή: Creative surgery and oncology; Том 14, № 2 (2024); 127-135 ; Креативная хирургия и онкология; Том 14, № 2 (2024); 127-135 ; 2076-3093 ; 2307-0501

Θεματικοί όροι: эпидуральная компрессия, spine, spine neoplasms, epidural compression, stereotactic radiation therapy, surgical treatment, позвоночник, позвоночника новообразования, стереотаксическая лучевая терапия, хирургическое лечение

Περιγραφή αρχείου: application/pdf

Relation: https://www.surgonco.ru/jour/article/view/948/599; Кит О.И., Закондырин Д.Е., Гринь А.А., Росторгуев Э.Е., Юндин С.В. Опыт лечения опухолей позвоночника, осложненных компрессией спинного мозга и его корешков. Инновационная медицина Кубани. 2022;1:5–11. DOI:10.35401/2500-0268-2022-25-1-5-11; Кит О.И., Вошедский В.И., Сакун П.Г., Гусарева М.А., Власов С.Г., Мусейко К.Н. и др. Опыт применения радиохирургического комплекса Novalis Tx в практике ФГБУ «НМИЦ онкологии» Минздрава России. Южно-Российский онкологический журнал. 2020;1(4):32–7. DOI:10.37748/2687-0533-2020-1-4-4; Bilsky M.H., Laufer I., Fourney D.R., Groff M., Schmidt M.H., Varga P.P., et al. Reliability analysis of the epidural spinal cord compression scale. J Neurosurg Spine. 2010;13(3):324–8. DOI:10.3171/2010.3.SPINE09459; Uei H., Tokuhashi Y., Maseda M., Nakahashi M., Sawada H., Nakayama E., et al. Comparison between minimally invasive spine stabilization with and without posterior decompression for the management of spinal metastases: a retrospective cohort study. J Orthop Surg Res. 2018;13(1):87. DOI:10.1186/s13018-018-0777-2; Fisher C.G., DiPaola C.P., Ryken T.C. A novel classification system for spinal instability in neoplastic disease: an evidencebased approach and expert consensus from the Spine. Spine (Phila Pa 1976). 2010;35:E1221–9. DOI:10.1097/BRS.0b013e3181e16ae2; Pennington Z., Ahmed A.K., Westbroek E.M., Cottrill E., Lubelski D., Goodwin M.L., et al. SINS Score and Stability: evaluating the need for stabilization within the uncertain category. World Neurosurg. 2019;128;1034–47. DOI:10.1016/j.wneu.2019.05.067; Maseda M., Uei H., Nakahashi M., Sawada H., Tokuhashi Y. Neurological outcome of treatment for patients with impending paralysis due to epidural spinal cord compression by metastatic spinal tumor. J Orthop Surg Res. 2019;14(1):291. DOI:10.1186/s13018-019-1348-x; Laufer I., Rubin D.G., Lis E., Cox B.W., Stubblefield M.D., Yamada Y., et al. The NOMS framework: approach to the treatment of spinal metastatic tumors. Oncologist 2013;18(6):744–51. DOI:10.1634/theoncologist.2012-0293; Balagamwala E.H., Naik M., Reddy C.A., Angelov L., Suh J.H., Djemil T., et al. Pain flare after stereotactic radiosurgery for spine metastases. J Radiosurg SBRT. 2018;5(2):99–105. PMID: 29657890; Guo L., Xu Q., Ke L., Wu Z., Zeng Z., Chen L., et al. The impact of radiosensitivity on clinical outcomes of spinal metastases treated with stereotactic body radiotherapy Cancer Medicine. 2023;12:13279–89. DOI:10.1002/cam4.6019; Correia D., Moullet B., Cullmann J., Heiss R., Ermiş E., Aebersold D.M., et al. Response assessment after stereotactic body radiation therapy for spine and non-spine bone metastases: results from a single institutional study. Radiat Oncol. 2022;17(1):37. DOI:10.1186/s13014-022-02004-7; Kelley K.D., Racareanu R., Sison C.P., Gogineni E., Rana Z., Gandhi S.V., et al. Outcomes in the radiosurgical management of metastatic spine disease. Adv Radiat Oncol. 2019;4(2):283–93. DOI:10.1016/j.adro.2018.10.007; Kim Y.J., Kim J.H., Kim K., Kim H.J., Chie E.K., Shin K. H., et al. The feasibility of spinal stereotactic radiosurgery for spinal metatstases with epidural cord compression. Cancer Res Treat. 2019;51(4):1324–35. DOI:10.4143/crt.2018.653; https://www.surgonco.ru/jour/article/view/948

Διαθεσιμότητα: https://www.surgonco.ru/jour/article/view/948
https://doi.org/10.24060/2076-3093-2024-14-2-127-135

Метастатическое поражение центральной нервной системы

Συγγραφείς: Д. Р. Насхлеташвили, С. М. Банов, А. Х. Бекяшев, А. В. Голанов, А. М. Зайцев, Г. Л. Кобяков, А. И. Пронин, А. В. Смолин

Πηγή: Malignant tumours; Том 13, № 3s2-1 (2023); 148-156 ; Злокачественные опухоли; Том 13, № 3s2-1 (2023); 148-156 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: метастатические опухоли головного мозга, таргетная терапия, химиотерапия, иммунотерапия, лучевая терапия, стереотаксическая лучевая терапия, радиохирургия, нейрохирургическое лечение

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1208/843; https://www.malignanttumors.org/jour/article/view/1208

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/1208
https://doi.org/10.18027/2224-5057-2023-13-3s2-1-148-156

Стереотаксическая лучевая терапия при почечно-клеточном раке. Опыт и непосредственные результаты

Συγγραφείς: Е. А. Степанович, П. Д. Демешко, С. Л. Поляков, И. И. Минайло

Πηγή: Malignant tumours; Том 12, № 3s1 (2022); 57-61 ; Злокачественные опухоли; Том 12, № 3s1 (2022); 57-61 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: общая выживаемость, стереотаксическая лучевая терапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1001/698; Percutaneous ablation or minimally invasive partial nephrectomy for cT1a renal masses? A propensity score-matched analysis / L. Bianchi [et al.] // Int J Urol .– 2022 .– Vol. 29, № 3 .– P. 222–228.; European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma : 2020 Update / M. Rouprêt [et al.] // Eur. Urol .– 2021 .– Vol. 79 (1) .– P. 62–79.; Роль стереотаксической лучевой терапии при почечно-клеточном раке / П. Д. Демешко [и др.] // Онколог. журн .– 2019 .– Т. 13, № 1 .– С. 110–116.; Stereotactic ablative radiation therapy for oligoprogressive renal cellcarcinoma / J. E. Schoenhals [et al.] // Adv. Radiat. Oncol .– 2021 .– Vol. 6 (5) .– P. 100692.; Stereotactic body radiotherapy for primary renal cell carcinoma and adrenal metastases / G. Kothari [et al.] // Chin. Clin. Oncol .– 2017 .– Vol. 6 (Suppl 2) .– P. 17.; Deschavanne, P. J. A review of human cell radiosensitivity in vitro / P. J. Deschavanne, B. Fertil // Int. J. Radiat. Oncol. Biol. Phys .– 1996 .– Vol. 34 .– P. 251–266.; Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in Vitro and in Vivo in human renal cell carcinoma xenografts / S. Ning [et al.] // Cancer .– 1997 .– Vol. 80 .– P. 2519–2528.; Radiotherapy for renal-cell carcinoma / G. De Meerleer [et al.] // Lancet Oncol .– 2014 .– Vol. 15 .– P. 170–177.; Kolesnick, R. Radiation and ceramide-induced apoptosis / R. Kolesnick, Z. Fuks // Oncogene .– 2003 .– Vol. 22 .– P. 5897–906.; Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling / S. Marathe [et al.] // J. Biol. Chem .– 1998 .– Vol. 273 .– P. 4081–4088.; Tumor response to radiotherapy regulated by endothelial cell apoptosis / M. Garcia-Barros Science .– 2003 .– Vol. 300 .– P. 1155–1159.; Elevated sphingomyelinase activity and ceramide concentration in serum of patients undergoing high dose spatially fractionated radiation treatment : implications for endothelial apoptosis / S. Sathishkumar [et al.] // Cancer. Biol. Ther .– 2005 .– Vol. 4 .– P. 979–986.; Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma / P. J. Wersall [et al.] // Acta. Oncol .– 2006 .– Vol. 45 .– P. 493–497.; The abscopal effect of radiation therapy / D. J. Craig [et al.] // Future. Oncol .– 2021 .– Vol. 17 (13) .– P. 1683–1694.; The abscopal effect : a review of pre-clinical and clinical advances / J. R. Janopaul-Naylor [et al.] // Int. J. Mol. Sci .– 2021 .– Vol. 22 (20) .– P. 11061.; The abscopal effect in the era of checkpoint inhibitors / O. Kodet [et al.] // Int. J. Mol. Sci .– 2021 .– Vol. 22 (13) .– P. 7204.; Abscopal effect in the radio and immunotherapy / A. M. Pevzner [et al.] // Radiat. Oncol. J .– 2021 .– Vol. 39 (4) .– P. 247–253.; Single fraction radiosurgery for the treatment of renal tumors / M. Staehler [et al.] // J. Urol .– 2015 .– Vol. 193, № 3 .– P. 771–775.; McBride, S. M. A phase 1 dose-escalation study of robotic radiosurgery in inoperable primary renal cell carcinoma / S. M. McBride, A. A. Wagner, I. D. Kaplan // Int. J. Radiat. Oncol. Biol. Phys .– 2013 .– Vol. 87, № 2 — P. 84.; A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma / C. Svedman [et al.] / / Acta. Oncol.– Vol. 45, № 7.– P. 870–875.; https://www.malignanttumors.org/jour/article/view/1001

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/1001
https://doi.org/10.18027/2224-5057-2022-12-3s1-57-61

LOCAL TREATMENT OPTIONS FOR COLORECTAL CANCER PATIENTS WITH LIVER OLIGOMETASTASES: A LITERATURE REVIEW ; ВАРИАНТЫ ЛОКАЛЬНОГО ЛЕЧЕНИЯ ОЛИГОМЕТАСТАТИЧЕСКОГО ПОРАЖЕНИЯ ПЕЧЕНИ ПРИ КОЛОРЕКТАЛЬНОМ РАКЕ: ОБЗОР ЛИТЕРАТУРЫ

Συγγραφείς: A. N. Moskalenko, V. k. Lyadov, I. V. Sagaydak, M. V. Chernykh, N. N. Britskaya, А. Н. Москаленко, В. К. Лядов, И. В. Сагайдак, М. В. Черных, Н. Н. Брицкая

Πηγή: Malignant tumours; Том 11, № 4 (2021); 29-38 ; Злокачественные опухоли; Том 11, № 4 (2021); 29-38 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: стереотаксическая лучевая терапия, liver resection, colorectal cancer, stereotactic radiation therapy, резекция печени, колоректальный рак

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/934/671; F. Bray, J. Ferlay, I. Soerjomataram et al. “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA. Cancer J. Clin., vol. 68, no. 6, pp. 394–424, Nov. 2018.; Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой Злокачественные новообразования в России в 2017 году (заболеваемость и смертность) М.: МНИОИ им. П.А. Герцена филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. илл. 250 с. ISBN 978-5-85502-243-8.; Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, et al. European Colorectal Metastases Treatment Group. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006 Sep;42 (14):2212-21. doi:10.1016/j.ejca.2006.04.012. Epub 2006 Aug 10. PMID:16904315.; Adam R, De Gramont A, Figueras J et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. The Oncologist 2012; 17:1225-1239.; Adam R, De Gramont A, Figueras J et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treatment Reviews 2015; 41:729-741.; Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13: 8–10.; Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. Oncotarget. 2015;6 (11):8491-8524. doi:10.18632/oncotarget.3455.; Guckenberger M., Lievens Y., Bouma AB., Collette L., Dekker A., deSouza NM, Dingemans AMC et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 2020 Jan;21 (1):e18-e28. doi:10.1016/S1470-2045(19)30718-1.; Ashworth AB, Senan S, Palma DA, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer 2014;15:346e55.; Yoo GS, Yu JI, Park W, Huh SJ, Choi DH. Prognostic factors in breast cancer with extracranial oligometastases and the appropriate role of radiation therapy. Radiat Oncol J 2015;33:301e9.; Conde Moreno AJ, Ferrer Albiach C, Muelas Soria R, Gonzalez Vidal V, Garcia Gomez R, Albert Antequera M. Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options. Radiat Oncol (London, England) 2014;9:258.; Ciliberto D, Prati U, Roveda L, Barbieri V, Staropoli N, Abbruzzese A, Caraglia M, Di Maio M, Flotta D, Tassone P, Tagliaferri P. Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. Oncol Rep. 2012 Jun;27 (6):1849-56. doi:10.3892/or.2012.1740. Epub 2012 Mar 22. PMID:22446591.; Araujo R, Gonen M, Allen P, Blumgart L, DeMatteo R, Fong Y, Kemeny N, Jarnagin W, D’Angelica M. Comparison between perioperative and postoperative chemotherapy after potentially curative hepatic resection for metastatic colorectal cancer. Ann Surg Oncol. 2013 Dec;20 (13):4312-21. doi:10.1245/s10434-013-3162-8. Epub 2013 Jul 30. PMID:23897009.; Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg. 2006 May;141 (5):460-6; discussion 466-7. doi:10.1001/archsurg.141.5.460. PMID:16702517.; Hur H, Ko YT, Min BS, Kim KS, Choi JS, Sohn SK, Cho CH, et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg. 2009 Jun;197 (6):728-36. doi:10.1016/j.amjsurg.2008.04.013. Epub 2008 Sep 11. PMID:18789428.; Lee WS, Yun SH, Chun HK, Lee WY, Kim SJ, Choi SH, et al. Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. J Clin Gastroenterol. 2008 Sep;42 (8):945-9. doi:10.1097/MCG.0b013e318064e752. PMID:18438208.; Figueras J, Torras J, Valls C, Llado L, Ramos E, Marti-Rague J, et al. Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon Rectum. 2007;50 (4):478–88.; Rees M, Tekkis PP, Welsh FK, O’Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247 (1):125–35.; Pulitanò C, Bodingbauer M, Aldrighetti L, de Jong MC, Castillo F, Schulick RD, et al. Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol. 2011 May;18 (5):1380-8. doi:10.1245/s10434-010-1459-4. Epub 2010 Dec 7. PMID:21136180.; Sawada Y., Sahara K,. Endo I., Sakamoto K., Honda G., Beppu T., Kotake K et al. Long-term outcome of liver resection for colorectal metastases in the presence of extrahepatic disease: A multi-institutional Japanese study. J Hepatobiliary Pancreat Sci 2020;27 (11):810-818. doi:10.1002/jhbp.810.; Homayounfar K, Bleckmann A, Conradi LC, Sprenger T, Lorf T, Niessner M et al. Metastatic recurrence after complete resection of colorectal liver metastases: impact of surgery and chemotherapy on survival. Int J Colorectal Dis. 2013 Jul;28 (7):1009-17. doi:10.1007/s00384-013-1648-2. Epub 2013 Feb 1. PMID:23371333; PMCID: PMC3712136.; Liu W, Sun Y, Zhang L, Xing BC. Negative surgical margin improved long-term survival of colorectal cancer liver metastases after hepatic resection: a systematic review and meta-analysis. Int J Colorectal Dis. 2015 Oct;30 (10):136573. doi:10.1007/s00384-015-2323-6. Epub 2015 Jul 23. PMID:26198997.; de Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg. 2008 Oct;248 (4):626-37. doi:10.1097/SLA.0b013e31818a07f1. PMID:18936576.; Sadot E, Groot Koerkamp B, Leal JN, Shia J, Gonen M, Allen PJ, DeMatteo RP, Kingham TP, Kemeny N, Blumgart LH, Jarnagin WR, DʼAngelica MI. Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate? Ann Surg. 2015 Sep;262 (3):476-85; discussion 483-5. doi:10.1097/SLA.0000000000001427. PMID:26258316; PMCID: PMC4533113.; Viganò L, Procopio F, Cimino MM, Donadon M, Gatti A, Costa G, Del Fabbro D, Torzilli G. Is Tumor Detachment from Vascular Structures Equivalent to R0 Resection in Surgery for Colorectal Liver Metastases? An Observational Cohort. Ann Surg Oncol. 2016 Apr;23 (4):1352-60. doi:10.1245/s10434-015-5009-y. Epub 2015 Dec 29. PMID:26714946.; Andreou A, Knitter S, Schmelzle M, Kradolfer D, Maurer MH, Auer TA, Fehrenbach U, Lachenmayer A, Banz V, Schöning W, Candinas D, Pratschke J, Beldi G. Recurrence at surgical margin following hepatectomy for colorectal liver metastases is not associated with R1 resection and does not impact survival. Surgery. 2021 May;169 (5):1061-1068. doi:10.1016/j.surg.2020.11.024. Epub 2020 Dec 30. PMID:33386128.; Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020 Sep 1;38 (25):2830-2838. doi:10.1200/JCO.20.00818. Epub 2020 Jun 2. PMID:32484754; PMCID: PMC7460150.; Sawrie SM, Fiveash JB, Caudell JJ. Stereotactic body radiation therapy for liver metastases and primary hepatocellular carcinoma: normal tissue tolerances and toxicity. Cancer Control. 2010 Apr;17 (2):111-9. doi:10.1177/107327481001700206. PMID:20404794.; Kennedy AS. Radiation oncology approaches in liver malignancies. Am Soc Clin Oncol Educ Book. 2014: e150-5. doi:10.14694/EdBook_AM.2014.34.e150. PMID:24857096.; Méndez Romero A, de Man RA. Stereotactic body radiation therapy for primary and metastatic liver tumors: From technological evolution to improved patient care. Best Pract Res Clin Gastroenterol. 2016 Aug;30 (4):603-16. doi:10.1016/j.bpg.2016.06.003. Epub 2016 Jun 25. PMID:27644908.; van der Pool AE, Mendez RA, Wunderink W, et al. Stereotactic body radiation therapy for colorectal liver metastases. Br.J. Surg. 97 [3], 377-382. 2010.; Scorsetti M, Comito T, Tozzi A, Navarria P, Fogliata A, Clerici E, et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol. 2015;141 (3):543-53. doi:10.1007/s00432-014-1833-x. PMID:25245052.; Ahmed KA, Caudell JJ, El-Haddad G, Berglund AE, Welsh EA, Yue B et al. Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016;95 (5):1399-1404. doi:10.1016/j.ijrobp.2016.03.050. PMID:27319288; PMCID: PMC7771381.; Joo JH, Park JH, Kim JC, Yu CS, Lim SB, Park IJ, et al. Local Control Outcomes Using Stereotactic Body Radiation Therapy for Liver Metastases From Colorectal Cancer. Int J Radiat Oncol Biol Phys. 2017 Nov 15;99 (4):876-883. doi:10.1016/j.ijrobp.2017.07.030. Epub 2017 Jul 31. PMID:29063852.; Vernaleone M, Bonomo P, Di Cataldo V, Saieva C, Masi L, Desideri I et al. Robotic stereotactic radiotherapy for liver oligometastases from colorectal cancer: a single-center experience. Radiol Med. 2019 Sep;124 (9):870-876. doi:10.1007/s11547-019-01042-8. Epub 2019 May 18. PMID:31104277.; Эффективность стереотаксической лучевой терапии у больных с метастатическим поражением печени / С.И. Ткачев, Ю.И. Патютко, С.В. Медведев [и др.] // Анналы хирургической гепатологии. – 2016. – Т. 21. – № 1. – С. 38-43.; Введение термина «ключевой узел» в области комбинированного лечения больных колоректальным раком с метастазами в печени / И. В. Сагайдак, А. В. Назаренко, С. И. Ткачев [и др.] // Сборник научных работ III Петербургского Международного онкологического форума «Белые ночи 2017», Санкт-Петербург, 22–24 июня 2017 года / ФГБУ «НИИ онкологии им. Н. Н. Петрова» Минздрава России. – Санкт-Петербург: АННМО «Вопросы онкологии», 2017. – С. 92.; Hao W., Binbin J., Wei Y,. Kun Y. Can Radiofrequency Ablation Replace Liver Resection for Solitary Colorectal Liver Metastasis? A Systemic Review and Meta-Analysis. Front. Oncol. 2020 2020 Nov 17;10:561669. doi:10.3389/fonc.2020.561669.; Meijerink MR, Puijk RS, van Tilborg AAJM, Henningsen KH, Fernandez LG, Neyt M, Heymans J et al. Radiofrequency and Microwave Ablation Compared to Systemic Chemotherapy and to Partial Hepatectomy in the Treatment of Colorectal Liver Metastases: A Systematic Review and Meta-Analysis. Cardiovasc Intervent Radiol. 2018;41 (8):11891204. doi:10.1007/s00270-018-1959-3. PMID:29666906; PMCID: PMC6021475.; Puijk RS, Ruarus AH, Vroomen LGPH et al. Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial BMC Cancer 2018 Aug 15;18 (1):821. doi:10.1186/s12885-018-4716-8.; Shady W, Petre EN, Do KG, Gonen M, Yarmohammadi H, Brown KT, et al. Percutaneous Microwave versus Radiofrequency Ablation of Colorectal Liver Metastases: Ablation with Clear Margins (A0) Provides the Best Local Tumor Control. J Vasc Interv Radiol. 2018 Feb;29 (2):268-275. e1. doi:10.1016/j.jvir.2017.08.021. Epub 2017 Dec 6. PMID:29203394; PMCID: PMC5803367.; Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg. 2007 Oct;246 (4):559-65; discussion 565-7. doi:10.1097/SLA.0b013e318155a7b6. PMID:17893492.; Kennedy TJ, Cassera MA, Khajanchee YS, Diwan TS, Hammill CW, Hansen PD. Laparoscopic radiofrequency ablation for the management of colorectal liver metastases: 10-year experience. J Surg Oncol. 2013 Mar;107 (4):324-8. doi:10.1002/jso.23268. Epub 2012 Sep 20. PMID:22996143.; Leung U, Kuk D, D’Angelica MI, Kingham TP, Allen PJ, DeMatteo RP, et al. Long-term outcomes following microwave ablation for liver malignancies. Br J Surg. 2015 Jan;102 (1):85-91. doi:10.1002/bjs.9649. Epub 2014 Oct 9. PMID:25296639; PMCID: PMC4593505.; Shady W, Petre EN, Gonen M, Erinjeri JP, Brown KT, Covey AM, et al. Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes--A 10-year Experience at a Single Center. Radiology. 2016 Feb;278 (2):601-11. doi:10.1148/radiol.2015142489. Epub 2015 Aug 12. PMID:26267832; PMCID: PMC4734163.; Cannon R, Ellis S, Hayes D, Narayanan G, Martin RC 2nd. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol. 2013 Apr;107 (5):544-9. doi:10.1002/jso.23280. Epub 2012 Oct 22. PMID:23090720.; Hosein PJ, Echenique A, Loaiza-Bonilla A, Froud T, Barbery K, Rocha Lima CM, Yrizarry JM, Narayanan G. Percutaneous irreversible electroporation for the treatment of colorectal cancer liver metastases with a proposal for a new response evaluation system. J Vasc Interv Radiol. 2014;25 (8):1233-1239. e2. doi:10.1016/j.jvir.2014.04.007.; Niessen C, Beyer LP, Pregler B, Dollinger M, Trabold B, Schlitt HJ, J et al. Percutaneous Ablation of Hepatic Tumors Using Irreversible Electroporation: A Prospective Safety and Midterm Efficacy Study in 34 Patients. J Vasc Interv Radiol. 2016;27 (4):480-6. doi:10.1016/j.jvir.2015.12.025.; Lee J, Shin IS, Yoon WS, Koom WS, Rim CH. Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review. Radiother Oncol. 2020 Apr;145:63-70. doi:10.1016/j.radonc.2019.12.004.; Wang C, Wang H, Yang W, Hu K, Xie H, Hu KQ, et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology. 2015 May;61 (5):1579-90. doi:10.1002/hep.27548. Epub 2015 Mar 20. PMID:25284802.; Littrup PJ, Aoun HD, Adam B, Krycia M, Prus M, Shields A. Percutaneous cryoablation of hepatic tumors: long-term experience of a large U. S. series. Abdom Radiol (NY). 2016 Apr;41 (4):767-80. doi:10.1007/s00261-016-0687-x.; Glazer DI, Tatli S, Shyn PB, Vangel MG, Tuncali K, Silverman SG. Percutaneous Image-Guided Cryoablation of He‑ patic Tumors: Single-Center Experience With Intermediate to Long-Term Outcomes. AJR Am J Roentgenol. 2017;209 (6):1381-1389. doi:10.2214/AJR.16.17582; Di Martino M, Rompianesi G, Mora-Guzmán I, Martín-Pérez E, Montalti R, Troisi RI. Systematic review and meta-analysis of local ablative therapies for resectable colorectal liver metastases. Eur J Surg Oncol. 2020 May;46 (5):772781. doi:10.1016/j.ejso.2019.12.003. Epub 2019 Dec 4. PMID:31862133.; Aliberti C, Tilli M, Benea G, Fiorentini G. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res. 2006 Sep-Oct;26 (5B): 3793-5. PMID:17094403.; Richardson AJ, Laurence JM, Lam VW. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. J Vasc Interv Radiol. 2013 Aug;24 (8):1209-17. doi:10.1016/j.jvir.2013.05.055. PMID:23885916; Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, Mambrini A, Montagnani F, Alessandroni P, Catalano V, Coschiera P. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012 Apr;32 (4):1387-95. Erratum in: Anticancer Res. 2013 Nov;33 (11):5211. PMID:22493375.; Martin RC 2nd, Scoggins CR, Schreeder M, Rilling WS, Laing CJ, Tatum CM, Kelly LR, Garcia-Monaco RD, Sharma VR, Crocenzi TS, Strasberg SM. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015 Oct 15;121 (20):3649-58. doi:10.1002/cncr.29534. Epub 2015 Jul 6. PMID:26149602.; Akinwande O, Dendy M, Ludwig JM, Kim HS. Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: A systematic review. Surg Oncol. 2017 Sep;26 (3):268-275. doi:10.1016/j.suronc.2017.05.003. Epub 2017 May 22. PMID:28807246.; Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Peeters M, Findlay M, Weaver A, Mills J, Wilson C, Adams R, Francis A, Moschandreas J, Virdee PS, Dutton P, Love S, Gebski V, Gray A; FOXFIRE trial investigators; SIRFLOX trial investigators; FOXFIRE-Global trial investigators, van Hazel G, Sharma RA. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017 Sep;18 (9):1159-1171. doi:10.1016/S1470-2045(17)30457-6. Epub 2017 Aug 3. PMID:28781171; PMCID: PMC5593813.; https://www.malignanttumors.org/jour/article/view/934

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/934
https://doi.org/10.18027/2224-5057-2021-11-4-29-38

Практические рекомендации по лекарственному лечению метастатических опухолей головного мозга

Συγγραφείς: Д. Р. Насхлеташвили, С. М. Банов, А. Х. Бекяшев, Т. Н. Борисова, Е. Р. Ветлова, А. В. Голанов, А. М. Зайцев, Г. Л. Кобяков, А. В. Смолин

Πηγή: Malignant tumours; Том 10, № 3s2-1 (2020); 134-144 ; Злокачественные опухоли; Том 10, № 3s2-1 (2020); 134-144 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: хирургическое лечение, таргетная терапия, химиотерапия, иммунотерапия, лучевая терапия, стереотаксическая лучевая терапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/756/521; https://www.malignanttumors.org/jour/article/view/756

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/756
https://doi.org/10.18027/2224-5057-2020-10-3s2-08

Modern Techniques for Cervical Cancer Radiotherapy

Συγγραφείς: P. A. Lushnikova, E. S. Sukhikh, P. V. Izhevsky, Ya. N. Sutygina, M. A. Tatarchenko, I. B. Pyzhova

Πηγή: Креативная хирургия и онкология, Vol 11, Iss 1, Pp 58-67 (2021)

Θεματικοί όροι: рак шейки матки, дистанционная лучевая терапия, брахитерапия, внутритканевая лучевая терапия, стереотаксическая лучевая терапия, адъювантная лучевая терапия, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Relation: https://www.surgonco.ru/jour/article/view/571; https://doaj.org/toc/2307-0501; https://doaj.org/toc/2076-3093; https://doaj.org/article/b2226cb1525a4c29b4bb55e0873f872b

Διαθεσιμότητα: https://doi.org/10.24060/2076-3093-2021-11-1-58-67
https://doaj.org/article/b2226cb1525a4c29b4bb55e0873f872b

Разработка и внедрение методики лучевой терапии в режиме гипофракционирования для метастатического поражения печени с учетом контроля дыхания

Συγγραφείς: Татарченко, Мария Алексеевна

Συνεισφορές: Сухих, Леонид Григорьевич

Θεματικοί όροι: стереотаксическая лучевая терапия, радиобиологический эффект, дозиметрический план лечения, линейный ускоритель, система активного контроля дыхания, Stereotactic body radiation therapy, radiobiological effect, treatment plan, linear accelerator, active breath control system, 03.06.01, 621.386.85:615.84:616.362-006.6

Περιγραφή αρχείου: application/pdf

Relation: Татарченко М. А. Разработка и внедрение методики лучевой терапии в режиме гипофракционирования для метастатического поражения печени с учетом контроля дыхания : научный доклад / М. А. Татарченко; Национальный исследовательский Томский политехнический университет (ТПУ), Управление магистратуры, аспирантуры и докторантуры (УМАД), Исследовательская школа физики высокоэнергетических процессов (ИШФВП); науч. рук. Л. Г. Сухих. — Томск, 2022.; http://earchive.tpu.ru/handle/11683/71025

Διαθεσιμότητα: http://earchive.tpu.ru/handle/11683/71025

IMMUNE EFFECTS OF STEREOTACTIC ABLATIVE RADIATION THERAPY IN PATIENTS WITH MALIGNANT TUMORS: LITERATURE REVIEW ; ИММУНОЛОГИЧЕСКИЕ ЭФФЕКТЫ СТЕРЕОТАКСИЧЕСКОЙ ЛУЧЕВОЙ ТЕРАПИИ ПРИ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЯХ РАЗЛИЧНЫХ ЛОКАЛИЗАЦИЙ: ОБЗОР ЛИТЕРАТУРЫ

Συγγραφείς: A. Yu. Zozulya, I. A. Baldueva, S. N. Novikov, А. Ю. Зозуля, И. А. Балдуева, С. Н. Новиков

Πηγή: Siberian journal of oncology; Том 19, № 5 (2020); 108-113 ; Сибирский онкологический журнал; Том 19, № 5 (2020); 108-113 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2020-19-5

Θεματικοί όροι: метастатический опухолевый процесс, radiotherapy, immunotherapy, stereotactic ablative radiotherapy, SABR, metastatic tumor, радиотерапия, иммунотерапия, стереотаксическая лучевая терапия, СТЛТ

Περιγραφή αρχείου: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/1585/801; O'Dell M., Stubblefield M. Cancer rehabilitation: principles and practice. Demos Medical Publishing, 2009. 1172 p.; Xing D., Siva S., Hanna G.G. The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool’s Gold or El Dorado? Clin Oncol (R Coll Radiol). 2019 Jul; 31(7): 432–443. doi:10.1016/j.clon.2019.04.006.; Mole R.H. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953 May; 26(305): 234–41. doi:10.1259/0007-1285-26-305-234.; Reynders K., Illidge T., Siva S., Chang J.Y., De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015 Jun; 41(6): 503–10. doi:10.1016/j.ctrv.2015.03.011.; Amaravadi R.K., Thompson C.B. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res. 2007 Dec 15; 13(24): 7271–9. doi:10.1158/1078-0432.CCR-07-1595.; Ngwa W., Irabor O.C., Schoenfeld J.D., Hesser J., Demaria S., Formenti S.C. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018 May; 18(5): 313–322. doi:10.1038/nrc.2018.6.; Marconi R., Strolin S., Bossi G., Strigari L. A meta-analysis of the abscopal effect in preclinical models: Is the biologically effective dose a relevant physical trigger? PLoS One. 2017 Feb 21; 12(2): e0171559. doi:10.1371/journal.pone.0171559.; Grass G.D., Krishna N., Kim S. The immune mechanisms of abscopal effect in radiation therapy. Curr Probl Cancer. 2016 Jan-Feb; 40(1): 10–24. doi:10.1016/j.currproblcancer.2015.10.003.; Barker H.E., Paget J.T., Khan A.A., Harrington K.J. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015 Jul; 15(7): 409–25. doi:10.1038/nrc3958.; Gerber S.A., Sedlacek A.L., Cron K.R., Murphy S.P., Frelinger J.G., Lord E.M. IFN-γ mediates the antitumor effects of radiation therapy in a murine colon tumor. Am J Pathol. 2013; 182(6): 2345–54. doi:10.1016/j.ajpath.2013.02.041.; Lee Y., Auh S.L., Wang Y., Burnette B., Wang Y., Meng Y., Beckett M., Sharma R., Chin R., Tu T., Weichselbaum R.R., Fu Y.X. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009; 114(3): 589–95. doi:10.1182/blood-2009-02-206870.; Matsumura S., Demaria S. Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation. Radiat Res. 2010 Apr; 173(4): 418–25. doi:10.1667/RR1860.1.; Ganss R., Ryschich E., Klar E., Arnold B., Hämmerling G.J. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 2002 Mar 1; 62(5): 1462–70.; Hallahan D., Kuchibhotla J., Wyble C. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res. 1996 Nov 15; 56(22): 5150–5.; Matsumura S., Wang B., Kawashima N., Braunstein S., Badura M., Cameron T.O., Babb J.S., Schneider R.J., Formenti S.C., Dustin M.L., Demaria S. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol. 2008; 181(5): 3099–107. doi:10.4049/jimmunol.181.5.3099.; Trujillo J.A., Sweis R.F., Bao R., Luke J.J. T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res. 2018 Sep; 6(9): 990–1000. doi:10.1158/2326-6066. CIR-18-0277.; Postow M.A., Callahan M.K., Barker C.A., Yamada Y., Yuan J., Kitano S., Mu Z., Rasalan T., Adamow M., Ritter E., Sedrak C., Jungbluth A.A., Chua R., Yang A.S., Roman R.A., Rosner S., Benson B., Allison J.P., Lesokhin A.M., Gnjatic S., Wolchok J.D. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012; 366(10): 925–31. doi:10.1056/NEJMoa1112824.; Golden E.B., Demaria S., Schiff P.B., Chachoua A., Formenti S.C. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013 Dec; 1(6): 365–72. doi:10.1158/2326-6066.CIR-13-0115.; Okwan-Duodu D., Pollack B.P., Lawson D., Khan M.K. Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. Am J Clin Oncol. 2015 Feb; 38(1): 119–25. doi:10.1097/COC.0b013e3182940dc3.; Tsui J.M., Mihalcioiu C., Cury F.L. Abscopal Effect in a Stage IV Melanoma Patient who Progressed on Pembrolizumab. Cureus. 2018 Feb 27; 10(2): e2238. doi:10.7759/cureus.2238.; Sato H., Suzuki Y., Yoshimoto Y., Noda S.E., Murata K., Takakusagi Y., Okazaki A., Sekihara T., Nakano T. An abscopal effect in a case of concomitant treatment of locally and peritoneally recurrent gastric cancer using adoptive T-cell immunotherapy and radiotherapy. Clin Case Rep. 2017 Feb; 5(4): 380–4. doi:10.1002/ccr3.758.; Van de Walle M., Demol J., Staelens L., Rottey S. Abscopal effect in metastatic renal cell carcinoma. Acta Clin Belg. 2017 Aug; 72(4): 245–249. doi:10.1080/17843286.2016.1201614.; Deipolyi A.R., Bromberg J.F., Erinjeri J.P., Solomon S.B., Brody L.A., Riedl C.C. Abscopal Effect after Radioembolization for Metastatic Breast Cancer in the Setting of Immunotherapy. J Vasc Interv Radiol. 2018 Mar; 29(3): 432–433. doi:10.1016/j.jvir.2017.10.007.; Sharabi A., Kim S.S., Kato S., Sanders P.D., Patel S.P., Sanghvi P., Weihe E., Kurzrock R. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. Oncologist. 2017 Jun; 22(6): 631–637. doi:10.1634/theoncologist.2016-0517.; Theelen WSME, Peulen H.M.U., Lalezari F., van der Noort V., de Vries J.F., Aerts J.G.J.V., Dumoulin D.W., Bahce I., Niemeijer A.N., de Langen A.J., Monkhorst K., Baas P. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019 Jul 11; 5(9): 1276–82. doi:10.1001/jamaoncol.2019.1478.; Phase II trial of salvage radiation therapy to induce systemic disease regression after progression on systemic immunotherapy [Internet]. URL: https://clinicaltrials.gov/ct2/show/NCT02710253 (cited 12.09.2019).; Anti-PD 1 brain collaboration ю radiotherapy: the ABC-X Study [Internet]. URL: https://clinicaltrials.gov/ct2/show/NCT03340129 (cited 12.09.2019).; Skrepnik T., Sundararajan S., Cui H., Stea B. Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab. Oncoimmunology. 2017 Jan 19; 6(3): e1283461. doi:10.1080/2162402X.2017.1283461.; Theurich S., Rothschild S.I., Hoffmann M., Fabri M., Sommer A., Garcia-Marquez M., Thelen M., Schill C., Merki R., Schmid T., Koeberle D., Zippelius A., Baues C., Mauch C., Tigges C., Kreuter A., Borggrefe J., von Bergwelt-Baildon M., Schlaak M. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma. Cancer Immunol Res. 2016; 4(9): 744–54. doi:10.1158/2326-6066.CIR-15-0156.; Sharabi A.B., Nirschl C.J., Kochel C.M., Nirschl T.R., Francica B.J., Velarde E., Deweese T.L., Drake C.G. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol Res. 2015 Apr; 3(4): 345–55. doi:10.1158/2326-6066.CIR-14-0196.; https://www.siboncoj.ru/jour/article/view/1585

Διαθεσιμότητα: https://www.siboncoj.ru/jour/article/view/1585
https://doi.org/10.21294/1814-4861-2020-19-5-108-113

Radiation-induced erectile dysfunction in patients with prostate cancer: current methods of radiotherapy ; Радиационно-индуцированная эректильная дисфункция у больных раком предстательной железы: современные технологии лучевого лечения

Συγγραφείς: R. V. Novikov, S. N. Novikov, V. V. Protoshchak, I. B. Dzhalilov, Р. В. Новиков, С. Н. Новиков, В. В. Протощак, И. Б. Джалилов

Συνεισφορές: ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России, ФГБОУ ВПО «Санкт-Петербургский государственный университет», ФГБОУ ВПО «Военно-медицинская академии имени С.М. Кирова» МО РФ

Πηγή: Cancer Urology; Том 16, № 3 (2020); 143-152 ; Онкоурология; Том 16, № 3 (2020); 143-152 ; 1996-1812 ; 1726-9776

Θεματικοί όροι: эректильная дисфункция, radiation therapy, brachytherapy, stereotactic radiation therapy, erectile dysfunction, лучевая терапия, брахитерапия, стереотаксическая лучевая терапия

Περιγραφή αρχείου: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1314/1202; Hamdy F.C., Donovan J.L., Lane J.A. et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016;375(15):1415-24. DOI:10.1056/ NEJMoa1606220.; Jackson W.C., Silva J., Hartman H.E. et al. Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys 2019;104(4):778-9. DOI:10.1016/j.ijrobp.2019.03.051.; Wang Z., Ni Y., Chen J. et al. The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis. World J Surg Oncol 2020;18(1):42. DOI:10.1186/s12957-020-01824-9.; Mohler J.L., Antonarakis E.S., Armstrong A.J. Prostate cancer, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019;17(5):479-505. DOI:10.6004/jnccn.2019.0023.; Mahase S.S., D'Angelo D., Kang J. et al. Trends in the use of stereotactic body radiotherapy for treatment of prostate cancer in the United States. JAMA Netw Open 2020;3(2):e1920471. DOI:10.1001/jamanetworkopen.2019.20471.; Gaither T.W., Awad M.A., Osterberg E.C. et al. The natural history of erectile dysfunction after prostatic radiotherapy: a systematic review and meta-analysis. J Sex Med 2017;14(9):1071-8. DOI:10.1016/j.jsxm.2017.07.010.; Mahmood J., Shamah A.A., Creed T.M. et al. Radiation-induced erectile dysfunction: recent advances and future directions. Adv Radiat Oncol 2016;1(3):161-9. DOI:10.1016/j.adro.2016.05.003.; Nolan M.W., Marolf A.J., Ehrhart E.J. et al. Pudendal nerve and internal pudendal artery damage may contribute to radiation-induced erectile dysfunction. Int J Radiat Oncol Biol Phys 2015;91(4):796-806. DOI:10.1016/j.ijrobp.2014.12.025.; Incrocci L. Radiotherapy for prostate cancer and sexual health. Transl Androl Urol 2015;4(2):124-30. DOI:10.3978/ j.issn.2223-4683.2014.12.08.; Ciabatti S., Ntreta M., Buwenge M. et al. Dominant intraprostatic lesion boosting in sexual-sparing radiotherapy of prostate cancer: a planning feasibility study. Med Dosim 2019;44(4):356-64. DOI:10.1016/j.meddos.2019.01.008.; McLaughlin P.W., Troyer S., Berri S. et al. Functional anatomy of the prostate: implications for treatment planning. Int J Radiation Oncology Biol Phys 2005;63(2): 479-91. DOI:10.1016/j.ijrobp.2005.02.036.; McLaughlin P.W., Narayana V., Meirovitz A. et al. Vessel-sparing prostate radiotherapy: dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRI. Vessel-sparing prostate radiotherapy: dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRI. Int J Radiat Oncol Biol Phys 2005;61(1):20-31. DOI:10.1016/j.ijrobp.2004.04.070.; Lee J.Y., Spratt D.E., Liss A.L., McLaughlin P.W. Vessel-sparing radiation and functional anatomy-based preservation for erectile function after prostate radiotherapy. Lancet Oncol 2016;17(5):e198-208. DOI:10.1016/S1470-2045(16)00063-2.; Новиков Р.В., Пономарева О.И., Летинский С.С., Новиков С.Н. Анатомо-топографическое обоснование «сосудосохраняющей» лучевой терапии рака предстательной железы. Экспериментальная и клиническая урология 2020;(2):84-91. DOI:10.29188/22228543-2020-12-2-84-91.; Dean R.C., Lue T.F. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am 2005;32(4):379-95. DOI:10.1016/j.ucl.2005.08.007.; Mulhall J.P., Yonover P.M. Correlation of radiation dose and impotence risk after three-dimensional conformal radiotherapy for prostate cancer. Urology 2001;58(5):828. DOI:10.1016/s0090-4295(01)01415-7.; Roach M. 3rd, Nam J., Gagliard G. et al. Radiation dose-volume effects and the penile bulb. Int J Radiat Oncol Biol Phys 2010;76(3):130-4. DOI:10.1016/j.ijrobp.2009.04.094.; Magli A., Giangreco M., Crespi M. et al. Erectile dysfunction after prostate threedimensional conformal radiation therapy. Correlation with the dose to the penile bulb. Strahlenther Onkol 2012; 188(11):997-1002. DOI:10.1007/s00066-012-0227-8.; Murray J., Gulliford S., Griffin C. et al. Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP Trial. Clin Transl Radiat Oncol 2020;21(1):77-84. DOI:10.1016/j.ctro.2019.12.006.; Rasmusson E., Gunnlaugsson A., Wieslander E. et al. Erectile dysfunction and absorbed dose to penile base structures in a randomized trial comparing ultrahypofractionated and conventionally fractionated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2020;107(1):143-51. DOI:10.1016/j.ijrobp.2020.01.022.; Zaorsky N.G., Yu J.B., McBride S.M. et al. Prostate Cancer Radiotherapy Recommendations in Response to COVID-19. Adv Radiat Oncol 2020. Online ahead of print. DOI:10.1016/j.adro.2020.03.010.; Fuller D.B. Prostate stereotactic body radiotherapy — methods, rationale, outcomes and future directions. Chapter in Stereotactic body radiotherapy. A practical guide. Eds.: A. Gaya, A. Mahadeva. London: Springer-Verlag, 2015. Pp. 195-224.; Канаев С.В., Новиков С.Н., Мельник Ю.С. и др. Методология стереотаксической лучевой терапии рака предстательной железы. Вопросы онкологии 2017;63(2):287-93.; Seppala J., Suilamo S., Tenhunen M. et al. Dosimetric comparison and evaluation of 4 stereotactic body radiotherapy techniques for the treatment of prostate cancer. Technol Cancer Res Treat 2017;16(2):238-45. DOI:10.1177/1533034616682156.; Hossain S., Xia P., Huang K. et al. Dose gradient near target-normal structure interface for nonisocentric Cyberknife and isocentric intensity-modulated body radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010;78(1):58-63. DOI:10.1016/j.ijrobp.2009.07.1752.; Spratt D.E., Lee J.Y., Dess R.T. et al. Vessel-sparing radiotherapy for localized prostate cancer to preserve erectile function: a single-arm phase 2 trial. Eur Urol 2017;72(4):617-24. DOI:10.1016/j.eururo.2017.02.007.; Samlali H., Udrescu C., Lapierre A. et al. Prospective evaluation of a specific technique of sexual function preservation in external beam radiotherapy for prostate cancer. Br J Radiol 2017;90(1078): 20160877. DOI:10.1259/bjr.20160877.; Gillan C., Kirilova A., Landon A. et al. Radiation dose to the internal pudendal arteries from permanent-seed prostate brachytherapy as determined by time-of-flight MR angiography. Int J Radiat Oncol Biol Phys 2006;65(3):688-93 DOI:10.1016/j.ijrobp.2006.01.037.; Chasseray M., Dissaux G., Bourbonne V. et al. Dose to the penile bulb and individual patient anatomy are predictive of erectile dysfunction in men treated with 125I low dose rate brachytherapy for localized prostate cancer. Acta Oncol 2019;58(7):1029-35. DOI:10.1080/0284186X.2019.1574981.; Van der Wielen G.J., Mulhall J.P., Incrocci L. Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: a critical review. Radiother Oncol 2007;84(2):107-13. DOI:10.1016/j.radonc.2007.07.018.; Mahmood J., Connors C.Q., Alexander A.A. et al. Cavernous nerve injury by radiation therapy may potentiate erectile dysfunction in rats. Int J Radiat Oncol Biol Phys 2017;99(3):680-8. DOI:10.1016/j.ijrobp.2017.06.2449.; Ashcraft K.A., Hannan J.L., Eichenbaum G. et al. Clarifying the relative impacts of vascular and nerve injury that culminate in erectile dysfunction in a pilot study using a rat model of prostate irradiation and a thrombopoietin mimetic. Int J Radiat Oncol Biol Phys 2019;103(5):1212-20. DOI:10.1016/j.ijrobp.2018.11.064.; Prado K., Chin A. How nervesparing technique has been applied to radiotherapy? Asian J Androl 2016;18(6):898-9. DOI:10.4103/1008-682X.184995.; Alsaid B., Bessede T., Diallo D. et al. Division of autonomic nerves within the neurovascular bundles distally into corpora cavernosa and corpus spongiosum components: immunohistochemical confirmation with three-dimensional reconstruction. Eur Urol 2011;59(6):902-9. DOI:10.1016/j.eururo.2011.02.031.; Liss A., Zhou J., Evans C. et al. Anatomic variability of the neurovascular elements defined by MRI. Brachytherapy 2014;13(1):S42-3. DOI:10.1016/j.brachy.2014.02.267.; Villers A., McNeal J.E., Redwine E.A. et al. The role of perineural space invasion in the local spread of prostatic adenocarcinoma. J Urol 1989;142(3):763-8. DOI:10.1016/s0022-5347(17)38881-x.; Chao K.K., Goldstein N.S., Yan D. et al. Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension? Int J Radiat Oncol Biol Phys 2006;65(4):999-1007. DOI:10.1016/j.ijrobp.2006.02.039.; Inoue S., Shiina H., Hiraoka T. et al. Retrospective analysis of the distance between the neurovascular bundle and prostate cancer foci in radical prostatectomy specimens: its clinical implication in nerve-sparing surgery. BJU Int 2009;104(8):1085-90. DOI:10.1111/j.1464-410X.2009.08592.x.; Cassidy R.J., Nour S.G., Liu T. et al. Reproducibility in contouring the neurovascular bundle for prostate cancer radiation therapy. Pract Radiat Oncol 2018;8(3):e125-31. DOI:10.1016/j.prro.2017.08.001.; Roach D., Holloway L.C., Jameson M.G. et al. Multi-observer contouring of male pelvic anatomy: highly variable agreement across conventional and emerging structures of interest. J Med Imaging Radiat Oncol 2019;63(2):264-71. DOI:10.1111/1754-9485.12844.; Cassidy R.J., Yang X., Liu T. et al. Neurovascular bundle-sparing radiotherapy for prostate cancer using MRI-CT registration: a dosimetric feasibility study. Med Dosim 2016;41(4):339-43. DOI:10.1016/j.meddos.2016.08.003.; Johansson A.K., Lennernas B., Isacsson U. Neurovascular bundle infiltration can explain local relapses using conformal radiotherapy of prostate cancer. Anticancer Res 2017;37(4):1825-30. DOI:10.21873/anticanres.11517.; Leiker A.J., Rezaeian N.H., Laine A.M. et al. Prostate cancer neurovascular element sparing with stereotactic ablative radiation therapy (SAbR): a pilot dosimetric study for the POTEN-C Trial. Int J Radiat Oncol Biol Phys 2018;102(3):e125. DOI:10.1016/j.ijrobp.2018.07.335.; Новиков Р.В. Фокальная брахитерапия рака предстательной железы: современные тенденции развития методики. Вестник Российского научного центра рентгенрадиологии Минздрава России 2017;17(2)(электронный журнал).; Peters M., van Son M.J., Moerland M.A. et al. MRI-Guided ultrafocal HDR brachytherapy for localized prostate cancer: median 4-year results of a feasibility study. Int J Radiat Oncol Biol Phys 2019;104(5):1045-53. DOI:10.1016/j.ijrobp.2019.03.032.; Andrzejewski P., Kuess P., Knausl B. et al. Feasibility of dominant intraprostatic lesion boosting using advanced photon-, proton- or brachytherapy. Radiother Oncol 2015;117(3):509-14. DOI:10.1016/j.radonc.2015.07.028.; Zaorsky N.G., Davis B.J., Nguyen P.L. et al. The evolution of brachytherapy for prostate cancer. Nat Rev Urol 2017;14(7):415-39. DOI:10.1038/nrurol.2017.76.; Eade T., Hruby G., Booth J. et al. Results of a prospective dose escalation study of linear accelerator-based virtual brachytherapy (BOOSTER) for prostate cancer; virtual HDR brachytherapy for prostate cancer. Adv Radiat Oncol 2019;4(4):623-30. DOI:10.1016/j.adro.2019.03.015.; Chen M., Zhang Q., Zhang C. et al. Comparison of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and multiparametric magnetic resonance imaging (MRI) in the evaluation of tumor extension of primary prostate cancer. Transl Androl Urol 2020;9(2):382-90. DOI:10.21037/tau.2020.03.06.; Zamboglou C., Thomann B., Koubar K. et al. Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histo-logy reference. Radiat Oncol 2018;13(1):81. DOI:10.1186/s13014-018-1036-8.; Bettermann A.S., Zamboglou C., Kiefer S. et al. [68Ga-]PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard-implications for focal radiotherapy planning in primary prostate cancer. Radiother Oncol 2019;141:214-9. DOI:10.1016/j.radonc.2019.07.005.; Feutren T., Herrera F.G. Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule: a systematic review. Prostate Int 2018;6(3):75-87. DOI:10.1016/j.prnil.2018.03.005.; Leiker A.J., Desai N.B., Folkert M.R. Rectal radiation dose-reduction techniques in prostate cancer: a focus on the rectal spacer. Future Oncol 2018;14(26):2773-88. DOI:10.2217/fon-2018-0286.; Karsh L.I., Gross E.T., Pieczonka C.M. et al. Absorbable hydrogel spacer use in prostate radiotherapy: a comprehensive review of phase 3 clinical trial published data. Urology 2018;115(1):39-44. DOI:10.1016/j.urology.2017.11.016.; Hamstra D.A., Mariados N., Sylvester J. et al. Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: secondary analysis of a phase 3 trial. Pract Radiat Oncol 2018;8(1):e7-15. DOI:10.1016/j.prro.2017.07.008.; Xiang H.F., Lu H., Efstathiou J.A. et al. Dosimetric impacts of endorectal balloon in Cyberknife stereotactic body radiation therapy (SBRT) for early-stage prostate cancer. J Appl Clin Med Phys 2017;18(3):37-43. DOI:10.1002/acm2.12063.; Ardekani M.A., Ghaffari H., Navaser M. et al. Effectiveness of rectal displacement devices in managing prostate motion: a systematic review. Strahlenther Onkol 2020. DOI:10.1007/s00066-020-01633-9. Online ahead of print.; Jaccard M., Lamanna G., Dubouloz A. et al. Dose optimization and endorectal balloon for internal pudendal arteries sparing in prostate SBRT. Phys Med 2019;61(1):28-32. DOI:10.1016/j.ejmp.2019.04.008.; https://oncourology.abvpress.ru/oncur/article/view/1314

Διαθεσιμότητα: https://oncourology.abvpress.ru/oncur/article/view/1314
https://doi.org/10.17650/1726-9776-2020-16-3-143-152

Radiotherapy for patients with locoregional and oligometastatic relapses of prostate cancer after radical prostatectomy ; Лучевая терапия больных с локорегионарными и олигометастатическими рецидивами рака предстательной железы после радикальной простатэктомии

Συγγραφείς: P. V. Bulychkin, S. I. Tkachev, V. B. Matveev, A. V. Klimov, F. A. Kossov, П. В. Булычкин, С. И. Ткачев, В. Б. Матвеев, А. В. Климов, Ф. А. Коссов

Πηγή: Cancer Urology; Том 16, № 3 (2020); 102-108 ; Онкоурология; Том 16, № 3 (2020); 102-108 ; 1996-1812 ; 1726-9776

Θεματικοί όροι: стереотаксическая лучевая терапия, recurrence of prostate cancer, radical prostatectomy, salvage radiotherapy, oligometastase, stereotactic radiation therapy, рецидив рака предстательной железы, радикальная простатэктомия, спасительная лучевая терапия, олигометастаз

Περιγραφή αρχείου: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1303/1197; Состояние онкологической помощи населению России в 2017 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. 236 с.; Briganti A., Karnes R.J., Gandaglia G. et al. Natural history of surgically treated high-risk prostate canсer. Urol Oncol 2015;33(4):163.e7.; Makarov D.V., Trock B.J., Humphreys E.B. et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate - specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69(6):1095-101. DOI:10.1016/j.eururo.2007.08.010.; Joniau S., Hsu C.Y., Lerut E. et al. A pretreatment table for the prediction of final histopothology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol 2007;51(2):388-96. DOI:10.1016/j.eururo.2006.06.051.; Cookson M.S., Aus G., Burnett A.L. et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer. The American Urological Association Prostate Guidelines for Localized Prostate Cancer. Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes. J Urol 2007;177:540-5. DOI:10.1016/j.juro.2006.10.097.; Boccon-Gibod L., Djavan W.B., Hammerer P. Management of prostatespecific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract 2004;58(4):382-90. DOI:10.1111/j.1368-5031.2004.00184.x.; Sciara A., Panebianco V., Calciccia S. Role of dynamic contrast-enchanced magnetic resonance (MRI) imaging and proton MR spectroscopic imaging in the detection of local racurrence after radical prostatectomy for prostate cancer. Eur Urol 2008;54:589-600. DOI:10.1016/j.eururo.2007.12.034.; Cirillo S., Petracchini M., Scotti L. et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assesslocal recurrence following radical prostatectomyusing T2-weighted and contrast-enhanced imaging. Eur Radiol 2009;19(3):761-9. DOI:10.1007/s00330-008-1174-8.; Ахвердиева Г.И. Топическая МРТ-диагностика локализованного рака предстательной железы и его рецидива после радикальной простатэктомии. Автореф. дис. . канд. мед. наук: 14.01.13. М., 2014. 126 с.; Liauw S.L., Pitroda S.P., Eggener S.E. et al. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonanceimaging. Int J Radiat Oncol Biol Phys 2013;85(2):378-84. DOI:10.1016/j.ijrobp.2012.05.015.; Linder B.J., Kawashima A., Woodrum D.A. et al. Early localization of recurrent prostate cancer after prostatectomy by endorectal coil magnetic resonance imaging. Can J Urol 2014;21(3):7283-9.; Коссов Ф.А., Булычкин П.В., Олимов Б.П. и др. Возможности мультипараметрической магнитно-резонансной томографии в персонализации «спасительной» лучевой терапии у больных с рецидивом рака предстательной железы. Вестник рентгенологии и радиологии 2018;99(2):91.; Perner S., Hofer M.D., Kim R. et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007;38:696-701. DOI:10.1016/j.humpath.2006.11.012.; Eiber M., Maurer T., Souvatzoglou M. et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2015;56:668-74. DOI:10.2967/jnumed.115.154153.; Morigi J.J., Stricker P.D., Van Leeuwen P.J. et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 2015;56:1185-90. DOI:10.2967/jnumed.115.160382.; Ткачев С.И., Булычкин П.В., Бердник А.В. и др. Гипофракциониро-ванная «спасительная» лучевая терапия больных с рецидивами рака предстательной железы после радикальной простатэктомии. Медицинская радиология и радиационная безопасность 2014;(6):43-8.; Ткачев С.И., Булычкин П.В., Михайлова А.В. и др. «Спасительная» лучевая терапия после радикальной простатэктомии в режиме гипофракционирования. Вопросы онкологии 2015;(5):782-4.; Ткачев С.И., Булычкин П.В., Матвеев В.Б. и др. Спасительная лучевая терапия рецидивов рака предстательной железы после радикальной простатэктомии. Онкоурология 2018;14(1):100-6. DOI:10.17650/1726-9776-2018-14-1-100-106.; Булычкин П.В., Ткачев С.И., Матвеев В.Б. и др. Простатспецифический антиген -предиктор эффективности спасительной лучевой терапии больных с рецидивами рака предстательной железы после радикальной простатэктомии. Онкоурология 2019;15(2):66-72. DOI:10.17650/1726-9776-2019-15-2-66-72.; Hellman S., Weichselbaum R.R. Oligometastases. J Clin Oncol 1995;13(1):8-10. DOI:10.1200/JCO.1995.13.1.8.; Yao H.H., Hong M.Kh., Corcoran N.M. et al. Advances in local and ablative treatment of oligometastasis in prostate cancer. Asia Pac J Clin Oncol 2014;10(4):308-21. DOI:10.1111/ajco.12256.; https://oncourology.abvpress.ru/oncur/article/view/1303

Διαθεσιμότητα: https://oncourology.abvpress.ru/oncur/article/view/1303
https://doi.org/10.17650/1726-9776-2020-16-3-102-108

Стереотаксическая лучевая терапия в лечении больных колоректальным раком с метастазами в печени.

Συγγραφείς: Ivanov, S.M., Иванов, С.М., Tkaceov, S.I., Ткачёв, С.И., Alieva, S.B., Алиева, С.Б., Medvedev, S.V., Медведев, С.В., Nazarenko, A.V., Назаренко, А.В., Glebovskaia, V.V., Глебовская, В.В., Borisova, T.N., Борисова, Т.Н., Trofimova, O.P., Трофимова, О.П., Romanov, D.S., Романов, Д.С., Abdujapparov, A.S., Абдужаппаров, А.С., Fedoseenko, D.I., Федосеенко, Д.И., Grișina, I.I., Гришина, И.И.

Πηγή: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 68 (4) 196-201

Θεματικοί όροι: Стереотаксическая лучевая терапия, метастатический колоректальный рак, метастатическое поражение печени, Stereotactic radiation therapy, metastatic colorectal cancer, liver metastases

Περιγραφή αρχείου: application/pdf

Relation: https://ibn.idsi.md/vizualizare_articol/132211; urn:issn:18570011

Διαθεσιμότητα: https://ibn.idsi.md/vizualizare_articol/132211

Radiation Treatment of Synchronous Gynaecologic Cancer: a Clinical Case

Συγγραφείς: P. A. Lushnikova, E. S. Sukhikh

Πηγή: Креативная хирургия и онкология, Vol 10, Iss 3, Pp 221-227 (2020)

Θεματικοί όροι: первично-множественные новообразования, аденокарцинома влагалища, рак эндометрия, дистанционная лучевая терапия, стереотаксическая лучевая терапия, брахитерапия, конформальная лучевая терапия, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Relation: https://www.surgonco.ru/jour/article/view/509; https://doaj.org/toc/2307-0501; https://doaj.org/toc/2076-3093; https://doaj.org/article/08f06b4fad9045229b0ae4e73b984e07

Διαθεσιμότητα: https://doi.org/10.24060/20763093-2020-10-3-221-227
https://doaj.org/article/08f06b4fad9045229b0ae4e73b984e07

Phase 1b multicenter study of the safety and efficacy of stereotactic body radiation therapy for extracranial renal cell carcinoma metastases in combination with tyrosine kinase inhibitors or checkpoint inhibitors (VOLGA STUDY). ; Стереотаксическая лучевая терапия экстракраниальных метастазов почечно-клеточного рака в комбинации с ингибиторами тирозинкиназы и иммунотерапией: первые результаты клинического исследования ib фазы (VOLGA STUDY)

Συγγραφείς: N. V. Dengina, T. Mitin, S. V. Gamayunov, S. Safina, Yu. M. Kreinina, I. V. Tsimafeyeu, Н. В. Деньгина, Т. В. Митин, С. В. Гамаюнов, С. З. Сафина, Ю. М. Крейнина, И. В. Тимофеев

Πηγή: Malignant tumours; Том 9, № 3 (2019); 57-64 ; Злокачественные опухоли; Том 9, № 3 (2019); 57-64 ; 2587-6813 ; 2224-5057

Θεματικοί όροι: иммунотерапия, stereotactic body radiotherapy, targeted therapy, immunotherapy, стереотаксическая лучевая терапия, таргетная терапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/674/464; Tsimafeyeu I, Zolotareva T, Varlamov S, et al. Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry. ClinGenitourin Cancer. 2017 Dec;15 (6):e1069-e1072.; Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J ClinOncol 2006;24:3101-3106.; Alongi F, Arcangeli S, Triggiani L, Mazzolaa R, Buglione di Monale e Bastiac M, Fersinoa S, Baiguini A, Jereczek-Fossa BA, Magrini SM. Stereotactic ablative radiation therapy in renal cell carcinoma: From oligometastatic to localized disease. Critical Reviews in Oncology/Hematology 2017;117:48-56; Dengina N, Tsimafeyeu I, Mitin T. Current role of radiotherapy for renal-cell carcinoma: review. Clinical Genitourinary Cancer 2017;15 (2):183 -187.; Cancer Genome Atlas Research Network, 2013. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43-49.; Kim WH, Kim DG, Han JH, Paek SH, Chung HT, Park CK., et al. Early significant tumor volume reduction after radiosurgery in brain metastases from renal cell carcinoma results in long-term survival. Int J RadiatOncolBiolPhys. 2012;82 (5):1749 - 55.; Amini, A., Altoos, B., Bourlon, M. T., Bedrick, E., Bhatia, S., Kessler, E. R., et al. Local control rates of metastatic renal cell carcinoma (RCC) to the bone usingstereotactic body radiation therapy: is RCC truly radioresistant? Pract. Radiat. Oncol. 2015;5 (6):e589 — e596.; Ranck, M. C., Golden, D. W., Corbin, K. S., Hasselle, M. D., Liauw, S. L., Stadler, W. M., et al. Stereotactic body radiotherapy for the treatment ofoligometastatic renal cell carcinoma. Am.J. Clin. Oncol. 2013;36 (6):589-595.; De Wolf K, Vermaelen K, De Meerleer G, Lambrecht BN, Ost P. The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy. Oncoimmunology. 2015 May 27;4 (10):e1042198.; Folkert MR, Timmerman RD. Stereotactic ablative body radiosurgery (SABR) or Stereotactic body radiation therapy (SBRT). Advanced Drug Delivery Reviews 2017;109:3-14.; Motzer RJ, Escudier B, McDermott DF, Geogre S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803 -1813.; Deacon J, Peckham MJ, Steel GG. The radioresponsiveness of human tumours and the initial slope of the cell survival curve. RadiotherOncol 1984;2 (4):317 - 323.; Ning S, Trisler K, Wessels BW, Knox SJ. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer. 1997;80 (12):2519 - 2528.; Garcia-Barros, M., Paris, F., Cordon-Cardo, C., Lyden, D., Rafii, S., Haimovitz-Friedman, A., et al. Tumor response to radiotherapyregulated by endothelial cell apoptosis. Science 2003;300 (5622):1155 -1159.; Qian, C. N., Huang, D., Wondergem, B., Teh, B. T. Complexity of tumorvasculature in clear cell renal cell carcinoma. Cancer 2009;115 (10 Suppl): 2282-2289.; De Meerleer G, Khoo V, Escudier B, Joniau S, Bossi A, Ost P., et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol. 2014 Apr;15 (4):e170-7.; Park S, Kim KH, Rhee WJ, LeeJ, Cho Y, Koom WS. Treatment outcome of radiation therapy and concurrent targeted molecular therapy in spinal metastasis from renal cell carcinoma. RadiatOncol J 2016;34 (2):128- 134.; Ishiyama H, Teh BS, Ren H, Chiang S, Tann A, Blanco AI, Paulino AC, Amato R. Spontaneous regression of thoracic metastases while progression of brain metastases after stereotactic radiosurgery and stereotactic body radiotherapy for metastatic renal cell carcinoma: abscopal effect prevented by the blood-brain barrier? ClinGenitourin Cancer 2012; 10 (3):196-8.; Wersall PJ, Blomgren H, Pisa P, Lax I, Kalkner KM, Svedman C. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. ActaOncol2006; 45 (4):493-7.; Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN, Formenti SC, Demaria S. DNA exonuclease Trex1 regulates radiotherapy-induced tumor immunogenicity. Nat Commun 2017;8:15618 DOI:10.1038; https://www.malignanttumors.org/jour/article/view/674

Διαθεσιμότητα: https://www.malignanttumors.org/jour/article/view/674
https://doi.org/10.18027/2224-5057-2019-9-3-57-64

Modern methods of ablation of malignant tumors of the liver ; Современные методы абляции злокачественных новообразований печени

Συγγραφείς: L. I. Moskvicheva, D. V. Sidorov, M. V. Lozhkin, L. O. Petrov, M. V. Zabelin, Л. И. Москвичева, Д. В. Сидоров, М. В. Ложкин, Л. О. Петров, М. В. Забелин

Πηγή: Research and Practical Medicine Journal; Том 5, № 4 (2018); 58-71 ; Research'n Practical Medicine Journal; Том 5, № 4 (2018); 58-71 ; 2410-1893 ; 10.17709/2409-2231-2018-5-4

Θεματικοί όροι: стереотаксическая лучевая терапия, hepatocellular carcinoma, hepatic metastases, radiofrequency ablation, microwave ablation, high-intensity focused ultrasound therapy, laser ablation, cryoablation, percutaneous ethanol injection, irreversible electroporation, stereotactic body radiation therapy, метастатическое поражение печени, радиочастотная абляция, микроволновая абляция, высокоинтенсивная фокусированная ультразвуковая терапия, лазерная абляция, криоабляция, химическая абляция, необратимая электропорация

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpmj.ru/rpmj/article/view/322/272; Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. Каприна А. Д., Ста-ринского В. В., Петровой Г. В. М.: МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИРЦ» Минздрава России; 2017, 250 с./Ma-lignant neoplasms in Russia in 2015 (morbidity and mortality). Edited by Kaprin A. D., Starinsky V. V., Petrova G. V. Moscow: P. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation; 2017, р. 250 (In Russian).; Состояние онкологической помощи населению России в 2017 году. Под ред. Каприна А. Д., Старинского В. В., Петровой Г. В. М.: МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2018, 236 с./The state of cancer care in Russia in 2017. Edited by Kaprin A. D., Starinsky V. V., Petrova G. V. Moscow: P. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation; 2018, р. 236 (In Russian).; Лунев С. В., Сельчук В. Ю., Чистяков С. С. Современные подходы к хирургическому лечению опухолей печени. Русский медицинский журнал. 2011;2:44-47./Lunev SV, Selchuk VYu, Chistyakov SS. Modern approaches to surgical treatment of liver tumors. Russian Medical Journal. 2011;2:44-47. (In Russian).; Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schal-ke M, Schlitt HJ. Treatment of colorectal liver metastases in Germany: A ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer. 2014 Nov 4;14:810. DOI:10.1186/1471-2407-14-810; de Haas RJ, Wicherts DA, Flores E, Ducreux M, Levi F, Paule B, et al. Tumor Marker Evolution: Comparison with Imaging for Assessment of Response to Chemotherapy in Patients with Colorectal Liver Metastases. Ann Surg Oncol. 2010 Apr;17 (4):1010-23. DOI:10.1245/s10434-009-0887-5.; Вишневский В. А., Ефанов М. Г., Икрамов Р. З., Чжао А. В. Опухоли печени: диагностика и хирургическое лечение. Доказательная гастроэнтерология. 2013;2:38-47./Vishnevsky VA, Efanov MG, Ikramov RZ, Zhao AV. Hepatic tumours: diagnostics and surgical treatment. Russian Journal of Evidence-Based Gastroenterology (Dokazatel'naya gastroenterologiya). 2013;2:38-47. (In Russian).; Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. Gastroenterology. 2004 Nov;127 (5 Suppl 1): S35-50.; Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359 (4):378-90. DOI:10.1056/NEJMoa0708857; Labib PL, Davidson BR, Sharma RA, Pereira SP. Locoregion-al therapies in cholangiocarcinoma. Hepat Oncol. 2017 Oct;4 (4):99-109. DOI:10.2217/hep-2017-0014; Hansen PD, Cassera MA, Wolf RF. Ablative technologies for hepatocellular, cholangiocarcinoma, and metastatic colorectal cancer of the liver. Surg Oncol Clin N Am. 2015 Jan;24 (1):97-119. DOI:10.1016/j.soc.2014.09.003.; Knavel EM, Brace CL. Tumor ablation: common modalities and general practices. Tech Vasc Interv Radiol. 2013 Dec;16 (4):192-200. DOI:10.1053/j.tvir.2013.08.002.; Napoletano C, Taurino F, Biffoni M, De Majo A, Coscarella G, Bellati F, et al. RFA strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients. Int J Oncol. 2008 Feb;32 (2):481-90.; Reuter NP, Woodall CE, Scoggins CR, McMasters KM, Martin RC. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent? J Gastrointest Surg. 2009 Mar;13 (3):486-91. DOI:10.1007/s11605-008-0727-0.; Agcaoglu O, Aliyev S, Karabulut K, El-Gazzaz G, Aucejo F, Pel-ley R, et al. Complementary use of resection and radiofrequency ablation for the treatment of colorectal liver metastases: an analysis of 395 patients. World J Surg. 2013 Jun;37 (6):1333-9. DOI:10.1007/s00268-013-1981-1; Razafindratsira Т, Isamber М, Evrard S. Complications of intraoperative radiofrequency ablation of liver metastases. HPB. 2011;13:15-23. https://doi.org/10.1111/j.1477-2574.2010.00243.x; Berber E, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. Ann Surg Oncol. 2008 Oct;15 (10):2757-64. DOI:10.1245/s10434-008-0043-7; Nielsen K, van Tilborg AA, Meijerink MR, Macintosh MO, Zon-derhuis BM, de Lange ES, et al. Incidence and treatment of local site recurrences following RFA of colorectal liver metastases. World J Surg. 2013 Jun;37 (6):1340-7. DOI:10.1007/s00268-013-1997-6.; Van Tilborg AA, Meijerink MR, Sietses C, Van Waesberghe JH, Mackintosh MO, Meijer S, et al. Long term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. Br J Radiol. 2011 Jun;84 (1002):556-65. DOI:10.1259/bjr/78268814.; Kim KH, Yoon YS, Yu CS, Kim TW, Kim HJ, Kim PN, et al. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases. J Korean Surg Soc. 2011 Jul;81 (1):25-34. DOI:10.4174/jkss.2011.81.1.25; Ruers T, Punt C, Van Coevorden F, Pierie JP, Borel-Rinkes I, Ledermann JA, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012 Oct;23 (10):2619-26. DOI:10.1093/annonc/mds053; Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, et al. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. J Natl Cancer Inst. 2017 Sep 1;109 (9). DOI:10.1093/jnci/djx015.; Kim YS, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013 Jan;58 (1):89-97. DOI:10.1016/j.jhep.2012.09.020; Pompili M, Mirante VG, Rondinara G, Fassati LR, Piscaglia F, Agnes S, et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl. 2005 Sep;11 (9):1117-26. DOI:10.1002/lt.20469; Brillet PY, Paradis V, Brancatelli G, Rangheard AS, Consigny Y, Plessier A, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma before liver transplantation: a prospective study with histopathologic comparison. AJR Am J Roentgenol. 2006 May;186 (5 Suppl): S296-305. DOI:10.2214/AJR.04.1927; Sun Y, Cheng Z, Dong L, Zhang G, Wang Y, Liang P. Comparison of temperature curve and ablation zone between 915-and 2450-MHz cooled-shaft microwave antenna: results in ex vivo porcine livers. Eur J Radiol. 2012 Mar;81 (3):553-7. DOI:10.1016/j.ejrad.2011.02.013.; Shady W, Petre EN, Do KG, Gonen M, Yarmohammadi H, Brown KT, et al. Percutaneous Microwave versus Radiofrequency Ablation of Colorectal Liver Metastases: Ablation with Clear Margins (A0) Provides the Best Local Tumor Control. J Vasc Interv Radiol. 2018 Feb;29 (2):268-275.e1. DOI:10.1016/j.jvir.2017.08.021.; Song P, Sheng L, Sun Y, An Y, Guo Y, Zhang Y. The clinical utility and outcomes of microwave ablation for colorectal cancer liver metastases. Oncotarget. 2017 Feb 9;8 (31):51792-51799. DOI:10.18632/oncotarget.15244.; Zhou F, Yu X, Liang P, Han Z, Cheng Z, Yu J, et al. Does primary tumor location impact the prognosis of colorectal liver metastases patients after microwave ablation? — Lessons from 10 years' experience. Oncotarget. 2017 Jun 28;8 (59):100791-100800. DOI:10.18632/oncotarget.18764.; Livraghi T, Meloni F, Solbiati L, Zanus G, Noto A, Goleffi O, et al. Complications of microwave ablation for liver tumors: results of a multicenter study. Cardiovasc Intervent Radiol. 2012 Aug;35 (4):868—74. DOI:10.1007/s00270-011-0241-8; Shibata T, Niinobu T, Ogata N, Takami M. Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer. 2000 Jul 15;89 (2):276-84.; Alexander ES, Wolf FJ, Machan JT, Charpentier KP, Beland MD, Iannuccilli JD, et al. Microwave ablation of focal hepatic malignancies regardless of size: A 9-year retrospective study of 64 patients. Eur J Radiol. 2015 Jun;84 (6):1083-90. DOI:10.1016/j. ejrad.2015.02.027; Huo YR, Eslick GD. Microwave ablation compared to radiofrequency ablation for hepatic lesions: a meta-analysis. J Vasc Interv Radiol. 2015 Aug;26 (8):1139-1146.e2. DOI:10.1016/j.jvir.2015.04.004.; Eng OS, Tsang AT, Moore D, Chen C, Narayanan S, Gannon CJ, et al. Outcomes of microwave ablation for colorectal cancer liver metastases: a single center experience. J Surg Oncol. 2015 Mar 15;111 (4):410-3. DOI:10.1002/jso.23849.; Sun AX, Cheng ZL, Wu PP, Sheng YH, Qu XJ, Lu W, et al. Clinical outcome of medium-sized hepatocellular carcinoma treated with microwave ablation. World J Gastroenterol. 2015 Mar 14;21 (10):2997-3004. DOI:10.3748/wjg.v21.i10.2997.; Ginsburg M, Zivin SP, Wroblewski K, Doshi T, Vasnani RJ, Van Ha TG. Comparison of Combination Therapies in the Management of Hepatocellular Carcinoma: Transarterial Chemoemboli-zation with Radiofrequency Ablation versus Microwave Ablation. J Vasc Interv Radiol. 2015 Mar;26 (3):330-41. DOI:10.1016/j.jvir.2014.10.047.; van den Bijgaart RJ, Eikelenboom DC, Hoogenboom M, Futter-er JJ, den Brok MH, Adema GJ. Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. Cancer Immunol Immunother. 2017 Feb;66 (2):247-258. DOI:10.1007/s00262-016-1891-9.; Dupre A, Melodelima D, Perol D, Chen Y, Vincenot J, Chapelon JY, Rivoire M. First Clinical Experience of Intra-Operative High Intensity Focused Ultrasound in Patients with Colorectal Liver Metastases: A Phase I-IIa Study. PLoS One. 2015 Feb 26;10 (2): e0118212. DOI:10.1371/journal.pone.0118212.; Mearini L. High intensity focused ultrasound, liver disease and bridging therapy. World J Gastroenterol. 2013 Nov 21;19 (43):7494-9. DOI:10.3748/wjg.v19.i43.7494.; Li JJ, Gu MF, Luo GY, Liu LZ, Zhang R, Xu GL. Complications of high intensity focused ultrasound for patients with hepatocellular carcinoma. Technol Cancer Res Treat. 2009 Jun;8 (3):217-24. DOI:10.1177/153303460900800306; Xu G, Luo G, He L, Li J, Shan H, Zhang R, Li Y, et al. Follow-up of high-intensity focused ultrasound treatment for patients with hepatocellular carcinoma. Ultrasound Med Biol. 2011 Dec;37 (12):1993-9. DOI:10.1016/j.ultrasmedbio.2011.08.011; Ng KK, Poon RT, Chan SC, Chok KS, Cheung TT, Tung H, Chu F, et al. High-intensity focused ultrasound for hepatocellular carcinoma. Ann Surg. 2011 May;253 (5):981-7. DOI:10.1097/SLA.0b013e3182128a8b.; Cheung TT, Fan ST, Chu FS, Jenkins CR, Chok KS, Tsang SH, et al. Survival analysis of high-intensity focused ultrasound ablation in patients with small hepatocellular carcinoma. HPB (Oxford). 2013 Aug;15 (8):567-73. DOI:10.1111/hpb.12025.; Wu F, Wang ZB, Chen WZ, Zou JZ, Bai J, Zhu H, et al. Advanced hepatocellular carcinoma: treatment with high intensity focused ultrasound ablation combined with transcatheter arterial embolization. Radiology. 2005 May;235 (2):659-67. DOI:10.1148/ra-diol.2352030916; Vogl TJ, Farshid P, Naguib NN, Darvishi A, Bazrafshan B, Mbal-isike E, et al. Thermal ablation of liver metastases from colorectal cancer: radiofrequency, microwave and laser ablation therapies. Radiol Med. 2014 Jul;119 (7):451-61. DOI:10.1007/s11547-014-0415-y; Di Costanzo GG, D'Adamo G, Tortora R, Zanfardino F, Mat-tera S, Francica G, Pacella CM. A novel needle guide system to perform percutaneous laser ablation of liver tumors using the multifiber technique. Acta Radiol. 2013 Oct;54 (8):876-81. DOI:10.1177/0284185113489825.; Tombesi P, Di Vece F, Sartori S. Laser ablation for hepatic metastases from neuroendocrine tumors. AJR Am J Roentgenol. 2015 Jun;204 (6): W732. DOI:10.2214/AJR.14.14242.; Facciorusso A, Serviddio G, Muscatiello N. Local ablative treatments for hepatocellular carcinoma: An updated review. World J Gastrointest Pharmacol Ther. 2016 Nov 6;7 (4):477-489. DOI:10.4292/wjgpt.v7.i4.477; Yu H, Burke CT. Comparison of Percutaneous Ablation Technologies in the Treatment of Malignant Liver Tumors. Semin Intervent Radiol. 2014 Jun;31 (2):129-37. DOI:10.1055/s-0034-1373788.; Eichler K, Zangos S, Gruber-Rouh T, Vogl TJ, Mack MG. Magnetic resonance-guided laser-induced thermotherapy in patients with oligonodular hepatocellular carcinoma: long-term results over a 15-year period. J Clin Gastroenterol. 2012 Oct;46 (9):796-801. DOI:10.1097/MCG.0b013e3182641806; Sartori S, Di Vece F, Ermili F, Tombesi P. Laser ablation of liver tumors: An ancillary technique, or an alternative to radiofrequency and microwave? World J Radiol. 2017 Mar 28;9 (3):91-96. doi:10.4329/wjr.v9.i3.91.; Di Costanzo GG, Tortora R, D'Adamo G, De Luca M, Lampasi F, Addario L, et al. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial. J Gastroenterol Hepatol. 2015 Mar;30 (3):559-65. DOI:10.1111/jgh.12791.; Qu J, Gao X, Chen Y, Zhou L, Wu Y, Feng Y, et al. Outcomes of ultrasound-guided percutaneous argon-helium cryoablation of hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2012 Nov;19 (6):674-84. DOI:10.1007/s00534-011-0490-6.; Glazer DI, Tatli S, Shyn PB, Vangel MG, Tuncali K, Silverman SG. Percutaneous Image-Guided Cryoablation of Hepatic Tumors: Single-Center Experience With Intermediate to LongTerm Outcomes. AJR Am J Roentgenol. 2017 Dec;209 (6):1381-1389. DOI:10.2214/AJR.16.17582; Kemeny N. The management of resectable and unresectable liver metastases from colorectal cancer. Curr Opin Oncol. 2010 Jul;22 (4):364-73. DOI:10.1097/CCO.0b013e32833a6c8a; Wu B, Xiao YY, Zhang X, Zhang AL, Li HJ, Gao DF. Magnetic resonance imaging-guided percutaneous cryoablation of hepatocellular carcinoma in special regions. Hepatobiliary Pancreat Dis Int. 2010 Aug;9 (4):384-92.; Rong G, Bai W, Dong Z, Wang C, Lu Y, Zeng Z, et al. Long-Term Outcomes of Percutaneous Cryoablation for Patients with Hepatocellular Carcinoma within Milan Criteria. PLoS One. 2015 Apr 7;10 (4): e0123065. DOI:10.1371/journal.pone.0123065; Xu K-C, Niu L-Z, He W-B, Hu Y-Z, Zuo J-S. Percutaneous cryosurgery for the treatment of hepatic colorectal metastases. World J Gastroenterol. 2008 Mar 7;14 (9):1430-6.; Shimizu T, Sakuhara Y, Abo D, Hasegawa Y, Kodama Y, Endo H, et al. Outcome of MR-guided percutaneous cryoabla-tion for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2009;16:816-823. https://doi.org/10.1007/s00534-009-0124-4; Bageacu S, Kaczmarek D, Lacroix M, Dubois J, Forest J, Porche-ron J. Cryosurgery for resectable and unresectable hepatic metastases from colorectal cancer. Eur J Surg Oncol. 2007 Jun;33 (5):590-6. DOI:10.1016/j.ejso.2007.01.003; Xu K-C, Niu L-Z, Zhou Q, Hu Y-Z, Guo D-H, Liu Z-P, et al. Sequential use of transarterial chemoembolization and percutaneous cryosurgery for hepatocellular carcinoma. World J Gastroenterol. 2009 Aug 7;15 (29):3664-9.; McCarley JR, Soulen MC. Percutaneous ablation of hepatic tumors. Semin Intervent Radiol. 2010 Sep;27 (3):255-60. DOI:10.1055/s-0030-1261783.; Mahnken AH, Bruners P, Gunther RW. Local ablative therapies in HCC: percutaneous ethanol injection and radiofrequency ablation. Dig Dis. 2009;27 (2):148-56. DOI:10.1159/000218347.; Kwon JH. Is percutaneous ethanol injection therapy still effective for hepatocellular carcinoma in the era of radiofrequency ablation? Gut Liver. 2010 Sep;4 Suppl 1: S105-12. DOI:10.5009/gnl.2010.4.S1.S105; Jansen MC, van Hillegersberg R, Chamuleau RA, van Delden OM, Gouma DJ, van Gulik TM. Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. Eur J Surg Oncol. 2005 May;31 (4):331-47. DOI:10.1016/j.ejso.2004.10.011; Giorgio A, Di Sarno A, De Stefano G, Scognamiglio U, Farel-la N, Mariniello A, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Res. 2011 Jun;31 (6):2291-5.; Ansari D, Andersson R. Radiofrequency ablation or percutaneous ethanol injection for the treatment of liver tumors. World J Gastroenterol. 2012 Mar 14;18 (10):1003-8. DOI:10.3748/wjg. v18.i10.1003; Ebara M, Okabe S, Kita K, Sugiura N, Fukuda H, Yoshika-wa M, et al. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year ob-servation. J Hepatol. 2005 Sep;43 (3):458-64. DOI:10.1016/j.jhep.2005.03.033; Dettmer A, Kirchhoff TD, Gebel M, Zender L, Malek NP, Panning B, et al. Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma. World J Gastroenterol. 2006 Jun 21;12 (23):3707-15.; Livraghi T, Lazzaroni S, Meloni F, Solbiati L. Risk of tumour seeding after percutaneous radiofrequency ablation for hepatocellular carcinoma. Br J Surg. 2005 Jul;92 (7):856-8. DOI:10.1002/bjs.4986; Lau WY, Leung TW, Yu SC, Ho SK. Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg. 2003 Feb;237 (2):171-9. DOI:10.1097/01.SLA.0000048443.71734.BF; Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005 Aug;54 (8):1151-6. DOI:10.1136/gut.2004.045203; Zhang YJ, Liang HH, Chen MS, Guo RP, Li JQ, Zheng Y, et al. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology. 2007 Aug;244 (2):599-607. DOI:10.1148/radi-ol.2442060826; Branco F, Bru C, Vilana R, Bianchi L, Alves de Mattos A. Percutaneous ethanol injection before liver transplantation in the hepatocellular carcinoma. Ann Hepatol. 2009 Jul-Sep;8 (3):220-7.; Zimmerman A, Grand D, Charpentier KP. Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives. J Hepatocell Carcinoma. 2017 Mar 13;4:49-58. DOI:10.2147/JHC.S129063.; Qasrawi R, Silve L, Burdio F, Abdeen Z, Ivorra A. Anatomically Realistic Simulations of Liver Ablation by Irreversible Electroporation: Impact of Blood Vessels on Ablation Volumes and Undertreatment. Technol Cancer Res Treat. 2017 Jan 1:1533034616687477. DOI:10.1177/1533034616687477.; Ruarus AH, Vroomen LGPH, Puijk RS, Scheffer HJ, Zonderhu-is BM, Kazemier G, et al. Irreversible Electroporation in Hepa-topancreaticobiliary Tumours. Can Assoc Radiol J. 2018 Feb;69 (1):38-50. DOI:10.1016/j.carj.2017.10.005.; Dollinger M, Muller-Wille R, Zeman F, Haimerl M, Niessen C, Beyer LP, et al. Irreversible electroporation of malignant hepatic tumors — alterations in venous structures at subacute follow-up and evolution at mid-term follow-up. PLoS One. 2015 Aug 13;10 (8): e0135773. DOI:10.1371/journal.pone.0135773.; Dollinger M, Zeman F, Niessen C, Lang SA, Beyer LP, Muller M, et al. Bile duct injury after irreversible electroporation of hepatic malignancies: evaluation of MR imaging findings and laboratory values. J Vasc Interv Radiol. 2016 Jan;27 (1):96-103. DOI:10.1016/j.jvir.2015.10.002; Niessen C, Beyer LP, Pregler B, Dollinger M, Trabold B, Schlit-t=HJ, et al. Percutaneous ablation of hepatic tumors using irreversible electroporation: a prospective safety and midterm efficacy study in 34 patients. J Vasc Interv Radiol. 2016 Apr;27 (4):480-6. DOI:10.1016/j.jvir.2015.12.025; Bhutiani N, Philips P, Scoggins CR, McMasters KM, Potts MH, Martin RCG. Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC). HPB (Oxford). 2016 Jul;18 (7):593-9. DOI:10.1016/j.hpb.2016.03.609; Donadon M, Solbiati L, Dawson L, Barry A, Sapisochin G, Greig PD, et al. Hepatocellular Carcinoma: The Role of Interventional Oncology. Liver Cancer. 2016 Nov;6 (1):34-43. DOI:10.1159/000449346; Lyu T, Wang X, Su Z, Shangguan J, Sun C, Figini M, et al. Irreversible electroporation in primary and metastatic hepatic malignancies. A review. Medicine (Baltimore). 2017 Apr;96 (17): e6386. DOI:10.1097/MD.0000000000006386.; Niessen C, Thumann S, Beyer L, Pregler B, Kramer J, Lang S, et al. Percutaneous Irreversible electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors. Sci Rep. 2017 Mar 7;7:43687. DOI:10.1038/srep43687; Scorseffi M, Comito T, Tozzi A, Navarria P, Fogliata A, Cleri-ci E, et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol. 2015 Mar;141 (3):543—53. doi:10.1007/s00432-014-1833-x; Mutsaers A, Greenspoon J, Walker-Dilks C, Swaminath A. Systematic review of patient reported quality of life following stereotactic ablative radiotherapy for primary and metastatic liver cancer. Radiat Oncol. 2017 Jun 29;12 (1):110. DOI:10.1186/s13014-017-0818-8.; Liu X, Song Y, Liang P, Su T, Zhang H, Zhao X, et al. Analysis of the factors affecting the safety of robotic stereotactic body radiation therapy for hepatocellular carcinoma patients. Onco Targets Ther. 2017 Nov 6;10:5289-5295. DOI:10.2147/OTT.S142025.; Moore A, Cohen-Naftaly M, Tobar A, Kundel Y, Benjaminov O, Braun M, et al. Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma. Radiat Oncol. 2017 Oct 19;12 (1):163. DOI:10.1186/s13014-017-0899-4; Деньгина Н. В., Мозерова Е. Я. Стереотаксическая лучевая терапия и локальная гипертермия в лечении опухолей различных локализаций. Практическая онкология. 2015;16 (4):162-173./Dengina NV, Mozerova EYa. Stereotactic body radiotherapy and local hyperthermia in the treatment of various malignant tumors. Practical Oncology. 2015;16 (4):162-173 (In Russian).; Kim TH, Park J-W, Kim BH, Kim DY, Moon SH, Kim SS, et al. Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma. Oncotarget. 2017 Dec 19;9 (3):4034-4043. DOI:10.18632/oncotarget.23428.; Mendez Romero A, Keskin-Cambay F, van Os RM, Nuyt-tens JJ, Heijmen BJM, IJzermans JNM, Verhoef C. Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy. Rep Pract Oncol Radiother. 2017 Mar-Apr;22 (2):126-131. DOI:10.1016/j.rpor.2016.10.003; Mahadevan A, Blanck O, Lanciano R, Peddada A, Sundar-araman S, D'Ambrosio D, et al. Stereotactic Body Radiotherapy (SBRT) for liver metastasis — clinical outcomes from the international multi-institutional RSSearch® Patient Registry. Radiat Oncol. 2018 Feb 13;13 (1):26. DOI:10.1186/s13014-018-0969-2.; https://www.rpmj.ru/rpmj/article/view/322

Διαθεσιμότητα: https://www.rpmj.ru/rpmj/article/view/322
https://doi.org/10.17709/2409-2231-2018-5-4-6

THE POSSIBILITIES OF MODERN METHODS OF ABLATION IN NON-RESECTABLE LOCALLY ADVANCED PANCREATIC CANCER ; ВОЗМОЖНОСТИ СОВРЕМЕННЫХ МЕТОДОВ АБЛЯЦИИ ПРИ НЕРЕЗЕКТАБЕЛЬНОМ МЕСТНО-РАСПРОСТРАНЕННОМ РАКЕ ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ

Συγγραφείς: L. I. Moskvicheva, L. O. Petrov, D. V. Sidorov, Л. И. Москвичева, Л. О. Петров, Д. В. Сидоров

Πηγή: Research and Practical Medicine Journal; Том 5, № 2 (2018); 86-99 ; Research'n Practical Medicine Journal; Том 5, № 2 (2018); 86-99 ; 2410-1893 ; 10.17709/2409-2231-2018-5-2

Θεματικοί όροι: фотодинамическая терапия, radiofrequency ablation, microwave ablation, high intensity focused ultrasound therapy, cryoablation, irreversible electroporation, stereotactic body radiotherapy, photodynamic therapy, радиочастотная абляция, микроволновая абляция, высокоинтенсивная фокусированная ультразвуковая терапия, криоабляция, необратимая электропорация, стереотаксическая лучевая терапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpmj.ru/rpmj/article/view/272/244; Состояние онкологической помощи населению России в 2016 году. Под редакцией Каприна А.Д., Старинского В.В., Петровой Г.В. М.: МНИОИ им. П. А. Герцена – филиал ФГБУ “ФМИРЦ” Минздрава России. 2017.; Камарли З.П., Туманбаев А.М., Доолотбеков С.М. Рак поджелудочной железы: эпидемиология, клиника, диагностика, лечение. Вестник КРСУ. 2013;13(1):117-122.; Котельников А.Г., Патютко Ю.И., Трякин А.А. Клинические рекомендации по диагностике и лечению злокачественных опухолей поджелудочной железы. Общероссийский союз общественных объединений Ассоциация онкологов России, 2014. с. 28.; Макаров Е.С., Нечушкин М.И. Современные возможности лучевоголеченияракаоргановбилиопанкреатодуоденальной зоны. Практическая онкология. 2004;5(2):135-144.; Girelli R, Frigerio I, Giardino A, Regi P, Gobbo S, Malleo G, et al. Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. Langenbecks Arch Surg. 2013 Jan;398(1):63-9. DOI:10.1007/s00423-012-1011-z; Liu Q, Zhai B, Yang W, Yu LX, Dong W, He YQ, et al. Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine. Mol Ther. 2009 Dec;17(12):2049-57. DOI:10.1038/mt.2009.221.; Zerbini A, Pilli M, Laccabue D, Pelosi G, Molinari A, Negri E, et al. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology. 2010 May;138(5):1931-42. DOI:10.1053/j.gastro.2009.12.051; Shah DR, Green S, Elliot A, McGahan JP, Khatri VP. Current oncologic applications of radiofrequency ablation therapies. World J Gastrointest Oncol. 2013;5:71-80. https://doi.org/10.4251/wjgo.v5.i4.71; Paiella S, Salvia R, Girelli R, Frigerio I, Giardino A, D’Onofrio M, et al. Role of local ablative techniques (Radiofrequency ablation and Irreversible Electroporation) in the treatment of pancreatic cancer. Updates Surg. 2016 Sep;68(3):307-311. DOI:10.1007/s13304-016-0385-9; Kallis Y, Phillips N, Steel A, Kaltsidis H, Vlavianos P, Habib N, Westaby D. Analysis of endoscopic radiofrequency ablation of biliary malignant strictures in pancreatic cancer suggests potential survival benefit. Dig Dis Sci. 2015 Nov;60(11):3449-55. doi:10.1007/s10620-015-3731-8.; Wu TT, Li HC, Li WM, Ao GK, Lin H, Zheng F, Song JY. Percutaneous Intraluminal Radiofrequency Ablation for Malignant Extra hepatic Biliary Obstruction: A Safe and Feasible Method. Dig Dis Sci. 2015;60(7):2158-63. Dig Dis Sci. 2015 Jul;60(7):2158-63. DOI:10.1007/s10620-015-3547-6; Wang J, Zhao L, Zhou C, Gao K, Huang Q, Wei B, Gao J. Percutaneous Intraductal Radiofrequency Ablation Combined with Biliary Stent Placement for Nonresectable Malignant Biliary Obstruction Improves Stent Patency but not Survival. Medicine (Baltimore). 2016 Apr;95(15):e3329. DOI:10.1097/MD.0000000000003329.; Rustagi T, Chhoda A. Endoscopic Radiofrequency Ablation of the Pancreas. Dig Dis Sci. 2017 Apr;62(4):843-850. DOI:10.1007/s10620-017-4452-y; Song TJ, Seo DW, Lakhtakia S, Reddy N, Oh DW, Park DH, et al. Initial experience of EUS guided radiofrequency ablation of unresectable pancreatic cancer. Gastrointest Endosc. 2016 Feb;83(2):440-3. DOI:10.1016/j.gie.2015.08.048; Pai M, Habib N, Senturk H, Lakhtakia S, Reddy N, Cicinnati VR, et al. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms andneuroendocrine tumors. World J Gastrointest Surg. 2015 Apr 27;7(4):52-9. DOI:10.4240/ wjgs.v7.i4.52.; Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image guided tumor ablation: standardization of terminology and reporting criteria – a 10-year update. J Vasc Interv Radiol. 2014 Nov;25(11):1691-705.e4. DOI:10.1016/j.jvir.2014.08.027; Lygidakis NJ, Sharma SK, Papastratis P, Zivanovic V, Kefalourous H, Koshariya M, et al. Microwave ablation in locally advanced pancreatic carcinoma – a new look. Hepatogastroenterology. 2007;54:1305–1310.; Carrafiello G, Ierardi AM, Fontana F, Petrillo M, Floridi C, Lucchina N, et al. Microwave ablation of pancreatic head cancer: safety and efficacy. J Vasc Interv Radiol. 2013 Oct;24(10):1513-20. DOI:10.1016/j.jvir.2013.07.005.; Van den Bijgaart RJE, Eikelenboom DC, Hoogenboom M, Fütterer JJ, den Brok MH, Gosse J. Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. J Vasc Interv Radiol. 2013 Oct;24(10):1513-20. DOI:10.1016/j.jvir.2013.07.005; Zhou Y. High-intensity focused ultrasound treatment for advanced pancreatic cancer. Gastroenterol Res Pract. 2014;2014:205325. DOI:10.1155/2014/205325.; Wu F. High intensity focused ultrasound: a noninvasive therapy for locally advanced pancreatic cancer. World J Gastroenterol. 2014 Nov 28;20(44):16480-8. DOI:10.3748/wjg.v20.i44.16480.; Diana M, Schiraldi L, Liu Y-Y, Memeo R, Mutter D, Pessaux P, Marescaux J. High intensity focused ultrasound (HIFU) applied to hepato-biliopancreatic and the digestive system – current state of the art and future perspectives. Hepatobiliary Surg Nutr. 2016 Aug;5(4):329-44. DOI:10.21037/hbsn.2015.11.03.; Wang K, Zhu H, Meng Z, Chen Z, Lin J, Shen Y, Gao H. Safety evaluation of high intensity focused ultrasound in patients with pancreatic cancer. Onkologie. 2013;36:88-92. DOI:10.1159/000348530; Sung HY, Jung SE, Cho SH, Zhou K, Han JY, Han ST, et al. Long-term outcome of high-intensity focused ultrasound in advanced pancreatic cancer. Pancreas. 2011;40(7):1080-1086. DOI:10.1097/mpa.0b013e31821fde24; Orsi F, Zhang L, Arnone P, Orgera G, Bonomo G, Vigna PD, et al. High-intensity focused ultrasound ablation: effective and safe therapy for solid tumors in difficult locations. AJR Am J Roentgenol. 2010 Sep;195(3):W245-52. DOI:10.2214/AJR.09.3321.; Gao HF, Wang K, Meng ZQ, Chen Z, Lin JH, Zhou ZH, et al. High intensity focused ultrasound treatment for patients with local advanced pancreatic cancer. Hepatogastroenterology. 2013 Nov-Dec;60(128):1906-10. DOI:10.5754/hge13498; Wang K, Chen Z, Meng Z, Lin J, Zhou Z, Wang P, et al. Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancer. Int J Hyperthermia. 2011;27(2):101-7. DOI:10.3109/02656736.2010.525588.; Li PZ, Zhu SH, He W, Zhu LY, Liu SP, Liu Y, et al. High-intensity focused ultrasound treatment for patients with unresectable pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2012;11(6):655-60. DOI:10.1016/s1499-3872(12)60241-0; Xiong LL, Hwang JH, Huang XB, Yao SS, He CJ, Ge XH, et al. Early clinical experience using high intensity focused ultrasound for palliation of inoperable pancreatic cancer. JOP. 2009;10(2):123-9.; Li T, Wang YN, Khokhlova TD, D’Andrea S, Starr F, Chen H, et al. Pulsed high intensity focused ultrasound (pHIFU) enhances delivery of doxorubicin in a preclinical model of pancreatic cancer. Cancer Res. 2015 Sep 15;75(18):3738-46. DOI:10.1158/00085472.CAN-15-0296; Lau PC-P, Zheng SF, Ng WT, Yu SC-H. Inoperable pancreatic adenocarcinoma rendered complete remission by high-intensity focused ultrasound concurrent with gemcitabine-capecitabine chemotherapy: Case report and topic review. J Dig Dis. 2012 Jan;13(1):60-4. DOI:10.1111/j.1751-2980.2011.00546.x; Zhao J, Zhao F, Shi Y, Deng Y, Hu X, Shen H. The efficacy of a new high intensity focused ultrasound therapy for locally advanced pancreatic cancer. J Cancer Res Clin Oncol. 2017 Oct;143(10):2105-2111. DOI:10.1007/s00432-017-2459-6.; Ханевич М.Д., Манихас Г.М. Криохирургия рака поджелудочной железы. СПб.: «Аграф+», 2011, 226 с.; Goel R, Anderson K, Slaton J, Schmidlin F, Vercellotti G, Belcher J, Bischof JC. Adjuvant approaches to enhance cryosurgery. J Biomech Eng. 2009 Jul;131(7):074003. DOI:10.1115/1.3156804; Rombouts SJE, Vogel JA, van Santvoort HC, van Lienden KP, van Hillegersberg R, Busch OR, et al. Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer. Br J Surg. 2015 Feb;102(3):182-93. DOI:10.1002/bjs.9716.; Xu K, Niu L, Yang D. Cryosurgery for pancreatic cancer. Gland Surg. 2013;2:30-39. Gland Surg. 2013 Feb;2(1):30-9. DOI:10.3978/j.issn.2227-684X.2013.02.02; Niu L, Chen J, He L, Liao M, Yuan Y, Zeng J, et al. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic pancreatic cancer. Pancreas. 2013 Oct;42(7):11439. DOI:10.1097/MPA.0b013e3182965dde.; He L, Niu L, Korpan NN, Sumida S, Xiao Y, Li J, et al. Clinical Practice Guidelines for Cryosurgery of Pancreatic Cancer. Pancreas. 2017 Sep;46(8):967-972. DOI:10.1097/MPA.0000000000000878.; Патютко Ю.И., Подлужный Д.В., Котельников А.Г., Сагайдак И.В. Криохирургический метод в лечении больных злокачественными опухолями поджелудочной железы. РАМН, Хирургическое отделение опухолей печени и поджелудочной железы. 2005 г. / Patyutko UI, Podluzhny DV, Kotelnikov AG, Sagaydak IV. Cryosurgical method in the treat; Li J, Chen X, Yang H, Wang X, Yuan D, Zeng Y, et al. Tumour cryoablation combined with palliative bypass surgery in the treatment of unresectable pancreatic cancer: a retrospective study of 142 patients. Postgrad Med J. 2011 Feb;87(1024):89-95. DOI:10.1136/pgmj.2010.098350; Al-Sakere B, Andre F, Bernat C, Connault E, Opolon P, Davalos RV, et al. Tumor ablation with irreversible electroporation. PloS one. 2007;2:1135. DOI:10.1371/journal.pone.0001135; Edelblute CM, Hornef J, Burcus NI, Norman T, Beebe SJ, Schoenbach K, et al. Controllable Moderate Heating Enhances the Therapeutic Efficacy of Irreversible Electroporation for Pancreatic Cancer. Sci Rep. 2017 Sep 18;7(1):11767. DOI:10.1038/ s41598-017-12227-4.; Wendler JJ, Fischbach K, Ricke J, Jürgens J, Fischbach F, Köllermann J, et al. Irreversible Electroporation (IRE): Standardization of Terminology and Reporting Criteria for Analysis and Comparison. Pol J Radiol. 2016 Feb 17;81:54-64. DOI:10.12659/ PJR.896034; Martin RC. Irreversible Electroporation of Locally Advanced Pancreatic Head Adenocarcinoma. J Gastrointest Surg. 2013 Oct;17(10):1850-6. DOI:10.1007/s11605-013-2309-z; Månsson C, Bergenfeldt M, Brahmstaedt R, Karlson B-M., Nygren P, Nilsson A. Safety and preliminary efficacy of ultrasound-guided percutaneous irreversible electroporation for treatment of localized pancreatic cancer. Anticancer Res. 2014 Jan;34(1):289-93.; Paiella S, Butturini G, Frigerio I, Salvia R, Armatura G, Bacchion M, et al. Safety and feasibility of Irreversible Electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study. DigSurg. 2015;32(2):90–97. Dig Surg. 2015;32(2):90-7. DOI:10.1159/000375323.; Månsson C, Brahmstaedt R, Nilsson A, Nygren P, Karlson B-M. Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy. Eur J Surg Oncol. 2016 Sep;42(9):1401-6. DOI:10.1016/j.ejso.2016.01.024; Vogel JA, Rombouts SJ, van Delden OM, Dijkgraaf MG, van Gulik TM, van Hooft JE, et al. Induction chemotherapy followed by resection or irreversible electroporation in locally advanced pancreatic cancer (IMPALA): A prospective cohort study. J Cancer Res Clin Oncol. 2017 Dec;143(12):2607-2618. doi:10.1007/s00432-017-2513-4; Lin M, Liang S, Wang X, Liang Y, Zhang M, Chen J, et al. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment. J Cancer Res Clin Oncol. 2017 Dec;143(12):2607-2618. DOI:10.1007/s00432-017-2513-4; Belfiore MP, Ronza FM, Romano F, PietroIanniello G, Lucia GD, Gallo C, et al. Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: Our preliminary experience. Int J Surg. 2015 Sep;21 Suppl 1:S34-9. DOI:10.1016/j.ijsu.2015.06.049; Деньгина Н.В., Родионов В.В. Основы лучевой терапии злокачественных новообразований: учебно-методическое пособие для врачей и студентов. Ульяновск: УлГУ, 2013. 87 с.; Zhu X, Ju X, Cao F, Fang F, Qing S, Shen Y, et al. Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinical trial. BMJ Open. 2016 Dec 1;6(12):e013220. DOI:10.1136/bmjopen-2016-013220.; Brunner T., Nestle U., Grosu A., Partridge M. SBRT in pancreatic cancer: what is the therapeutic windows? Radiother Oncol. 2015 Jan;114(1):109-16. DOI:10.1016/j.radonc.2014.10.015; Деньгина Н.В., Мозерова Е.Я. Стереотаксическая лучевая терапия и локальная гипертермия в лечении опухолей различных локализаций. Практическая онкология. 2015;16(4):162-73.; Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015 Jul;54(7):979-85. DOI:10.3109/0284186X.2015.1004367; Zhu X, Li F, Ju X, Cao F, Cao Y, Fang F, et al. Prognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer. Cancer Med. 2017 Oct;6(10):2263-2270. DOI:10.1002/cam4.1164; Dagoglu N, Callery M, Moser J, Tseng J, Kent T, Bullock A, et al. Stereotactic Body Radiotherapy (SBRT) Reirradiation for Recurrent Pancreas Cancer. J Cancer. 2016 Jan 10;7(3):283-8. DOI:10.7150/jca.13295.; Bown SG, Rogowska AZ, Whitelaw DE, Lees WR, Lovat LB, Ripley P, et al. Photodynamic therapy for cancer of the pancreas. Gut. 2002;50:549-557. https://doi.org/10.1136/gut.50.4.549; Huggett MT, Jermyn M, Gillams A, Illing R, Mosse S, Novelli M, et al. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br J Cancer. 2014 Apr 2;110(7):1698-704. DOI:10.1038/bjc.2014.95; https://www.rpmj.ru/rpmj/article/view/272

Διαθεσιμότητα: https://www.rpmj.ru/rpmj/article/view/272
https://doi.org/10.17709/2409-2231-2018-5-2-10